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Abstract
Growth plate chondrocytes are the driving force of long bone elongation and they
accomplish this vital task, in part, by producing, remodeling, and finally mineralizing the cartilage
tissue that makes up the growth plate. This mineralized tissue is turned over again as bone
forming cells invade and began the process of turning mineralized cartilage into bone.
Chondrocytes undergo a distinct series of observable phases as they move through this process
transitioning from a stage of proliferation to one of hypertrophy and finally capillary invasion.
Chondrocytes produce matrix vesicles (MVs) that they release into the growth plate and that
attach to collagen in the extracellular matrix (ECM). These MVs are involved in chondrocyte
regulation, tissue remodeling, and matrix mineralization.
This entire process is highly regulated by various factors and hormones. 1α,25dihydroxyvitamin D3 [1α,25(OH)2D3] is a well-studied hormone with known regulation of both
chondrocytes and MVs. With the recent discovery of selectively exported microRNA in growth
plate MVs there is the possibility of an additional regulator of growth plate maturation. The central
hypothesis of this work was that MV microRNA are able to regulate growth plate chondrocytes
and that the production and packaging of MV microRNA is regulated by 1α,25(OH)2D3.
Specific aim 1 determined whether microRNA were selectively exported in MVs, if those
microRNA remain protected within the MVs, if certain microRNA are found in ex-vivo tissue, and
the ability of specific microRNA to regulate growth plate chondrocytes.

Specific aim 2

determined the regulatory potential of 1α,25(OH)2D3 on microRNA production and packaging into
MVs and the known mRNA and pathways targeted by the exported microRNA that were
differentially expressed following 1α,25(OH)2D3 treatment as well as the impact of 1α,25(OH)2D3
on MV endocytosis and the release of microRNA from MVs. Specific aim 3 examined the
transcriptome following specific microRNA transfections and adapted an approach to target the
interactions between specific tagged microRNA and the corresponding mRNA followed by
RNAseq of the mRNA for the purpose of pathway analysis.
Asmussen | MicroRNA in the Mammalian Growth Plate: Matrix Vesicles and 1α,25-Dihydroxyvitamin D3
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Summary
This thesis aimed to further elucidate the role of extracellular MV microRNA found in the
mammalian growth plate. This was done by examining the ability of specific MV microRNA to
regulate growth plate chondrocytes and investigating multiple aspects of the MV microRNA
lifecycle including regulation during production and packaging, the release within the ECM, MV
endocytosis, and what mRNA and pathways the MV microRNA are regulating within
chondrocytes. The work was carried out both in vitro using a wide-ranging array of assays and
visualization tools and in silico analyzing small RNA sequencing and RNA probe multiplex data.
Work began with the bioinformatic analysis of existing small RNAseq data followed by the in vitro
examination of chondrocytes responding to microRNA transfection. Expanding on this we began
investigating the role that 1α,25(OH)2D3 plays with respect to the packaging and release of MV
microRNA. Finally, we examined the direct regulation that these microRNAs exert on the cells.
RNAseq data examining the population of small RNA molecules found in resting zone
(RC) and growth zone (GC) chondrocytes and the MVs that they produce were analyzed to
examine zonal regulation and compile a list of specific microRNAs for detailed in vitro
investigation. MicroRNA were found to make up zone-specific populations in the RC and GC cells
and MVs; moreover, a subpopulation of select microRNA were exported within MVs into the ECM.
When comparing the chondrocytes from the two zones and MVs from the two zones a far larger
number of microRNA differed between the MVs than between the chondrocytes. Four microRNA
were selected, three being disproportionately found in the MVs while one microRNA was present
at relatively high levels in all groups. These microRNA were transfected into chondrocytes and a
wide host of phenotypic changes and activity were measured to assess effects on proliferation,
apoptosis, ECM components, factor production, and enzyme activity. Of the four select microRNA
under investigation two stood out (22-3p and 122-5p) for their impact on the proliferation, ECM
composition, and factor production of both RC and GC chondrocytes as well as the angiogenic
activity of HUVEC cells. Attempts were made to localize and validate specific microRNA in ex vivo
Asmussen | MicroRNA in the Mammalian Growth Plate: Matrix Vesicles and 1α,25-Dihydroxyvitamin D3
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tissue slices to pinpoint their location but due to collagen’s autofluoresence and insufficient
microscope resolution, the results were inconclusive. Further validation of the specific microRNAs
was successfully carried out using RT-qPCR and the NanoString’s nCounter system on ex vivo
tissue samples. Combining the bioinformatic analysis that microRNA is being selectively exported
from the cells (to such a degree that some microRNA had no copies remaining behind in the cell
population) and the phenotypic response from chondrocytes to these exported microRNA, we
have compelling evidence that the microRNAs are being packaged within MVs for a regulatory
purpose. Remaining unanswered is how these microRNAs make their way back into the cells and
whether they fall under the control of known growth plate regulators.
With the regulatory role of microRNA in the MVs established we wanted to see if
1α,25(OH)2D3 was involved in aspects of the MV microRNA lifecycle. We decided to examine the
role of 1α,25(OH)2D3 in regulating the production and/or packaging of microRNA by GC
chondrocytes, if it released microRNA from the MVs, and if it aided MV or microRNA endocytosis.
GC chondrocytes were treated with 1α,25(OH)2D3 for 24 hours and the small RNA in the cells and
MVs were sequenced. We were surprised to find very little change between the cell populations
with virtually all of the differential expression taking place in the MVs. The chondrocytes exported
a select population of microRNA in MVs, confirming previous observations, with an apparent
coordinated regulation of microRNA production and packaging taking place in response to
1α,25(OH)2D3 treatment. This resulted in markedly different MV microRNA populations but
virtually identical cell microRNA populations. The differentially expressed microRNAs in the MV
population as compared to the parent cells were searched for known connections to
musculoskeletal pathways, mRNAs, and tissues. The majority of microRNA were at most only
associated with musculoskeletal related tissues and had no mRNA or pathway information
indicating a large area of further investigation.
In order to look at various aspects of the MV microRNA lifecycle we began by examining
the ability of 1α,25(OH)2D3 to release microRNA from the MVs as it is known to initiate breakdown
of the MV’s phospholipid membrane. Surprisingly the microRNA was not released free into

Asmussen | MicroRNA in the Mammalian Growth Plate: Matrix Vesicles and 1α,25-Dihydroxyvitamin D3

13

solution as they remained protected from RNase activity indicating either the presence of a
protective carrier protein or lipid microcompartment or that a subpopulation of MVs houses the
microRNA. This result was unexpected but provides further emphasis for the likelihood of the MV
microRNA being a regulatory factor in the growth plate as the microRNA remain protected from
the near ubiquitous presence of RNase within tissues.
We decided to further examine potential paths of microRNA reentry into cells by staining
MVs with a lipophilic dye, incubating them with GC chondrocytes with either vehicle or
1α,25(OH)2D3 treatment, applying a nuclear counter stain to the cells, and imaging them in order
to quantify how many cells were in the process of endocytosing stained MVs. When six or more
distinct green dots, indicating MVs, were observed on a cell it was considered positively stained.
Percent of positively stained chondrocytes increased with 1α,25(OH)2D3 treatment. This indicates
an increase in the binding of MVs to chondrocytes due to either or both responding to
1α,25(OH)2D3 by increasing their binding potential or possibly the creation of MV fragments that
are produced as MVs respond to 1α,25(OH)2D3 by breaking down their lipid membrane leaving
an increased number of stained vesicle fragments for binding. In either scenario an increase in
chondrocyte to MV exposure appears to occur and given that the microRNA may well be bound
to the inner leaflet of the MVs even a population of MV fragments could be delivering a regulatory
message to the chondrocytes.
With most of the selectively exported microRNA having only bioinformatically predicted
activity and no detailed knowledge of their specific action in growth plate chondrocytes we looked
into an approach to determine the target mRNAs for certain microRNA in our specific cells. We
transfected biotin tagged microRNA mimics into cells and then used streptavidin coated magnetic
beads to pull down the tagged microRNA and any attached RNA. The beads were then
extensively washed and the RNA isolated for long read sequencing on a benchtop sequencer.
Resulting fastq files were filtered and aligned to the rat cDNA transcriptome and gene IDs were
determined. Differential expression analysis was conducted between each microRNA group and
the negative control group and it was found that the majority of differentially expressed mRNA
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were not shared between the five comparisons and largely unique for each microRNA under
examination. The binding energies of the microRNA against the 3` UTR of the up-regulated genes
were calculated and found to be on the higher end but well within commonly accepted values for
microRNA to mRNA binding energies. An introductory pathway analysis of the differentially
expressed mRNA was conducted to begin to examine what phenotypic effects might be resulting
from these microRNA.
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Specific Aims
RNA molecules were initially discovered in MVs in 1969 though believed at the time to
most likely be an artifact.[1] Their presence was confirmed in 2016 at which time small RNA
molecules, specifically microRNA, had been discovered and the technology to sequence and
analyze the RNA was widely available.[2] The purpose of these MV microRNA in the growth plate
and their ability to regulate the chondrocytes was unclear.
1α,25(OH)2D3 is a well-known regulator of growth zone chondrocytes and the
mineralization process that occurs in the growth plate.[3] This regulation occurs through
interactions with the chondrocytes and the MVs as both have receptors for 1α,25(OH)2D3.[4] In
addition to responding to 1α,25(OH)2D3, GC chondrocytes are able to metabolize 25hydroxyvitamin D3 (25OHD3) to 1α,25(OH)2D3 on their own.[5,6] MVs respond to 1α,25(OH)2D3
by releasing enzymes that are able to activate latent TGF-β in the ECM that, in turn, regulates
chondrocyte 1α,25(OH)2D3 production.[7,8] 1α,25(OH)2D3 is also able to regulate aspects of the
production of MVs and initiate MV breakdown once they are in the ECM.[7]
From this standpoint a working hypothesis was put together:
The specifically packaged microRNAs in matrix vesicles regulate
the maturation of chondrocytes in the growth plate. Packaging and
release of microRNA is a well-regulated process controlled by
hormones and local factors, specifically 1α,25-dihydroxyvitamin D3.
Previous work in our lab had sequenced RNA from growth plate chondrocytes and MVs and found
selective packaging of microRNA in MVs.[2] Additionally, the MVs provided protection to the small
RNAs from RNase activity when in solution. The selective export in MVs and a protective lipid
membrane suggested the potential for MV microRNA to regulate growth plate chondrocytes.
Aim 1:
Determine the role of matrix vesicle microRNAs in the growth and
differentiation of resting zone and growth zone chondrocytes.
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This was accomplished by determining that a zonal production of microRNA occurs in the
growth plate with RC and GC chondrocytes and MVs each containing a distinct population of
microRNA. Both RC and GC zones export a selective population of microRNA into MVs and these
microRNAs are protected in suspension from RNase treatment. This work was published in
collaboration with Dr. Zhao Lin and is reprinted here in the section “MicroRNA Contents in Matrix
Vesicles Produced by Growth Plate Chondrocytes are Cell Maturation Dependent”. My
bioinformatic analysis is found in the first six tables of the paper and in figures three and five.
Following this, we analyzed the small RNA sequence data from growth plate chondrocytes and
MVs and selected three microRNA that were selectively exported in MVs and had a minimal
presence within chondrocytes and one microRNA that made up a relatively large portion of both
chondrocyte and MV microRNA populations. These four microRNA were transfected into RC and
GC chondrocytes and phenotypic changes investigated through a variety of assays.[9] We
examined effects on proliferation (DNA content and EdU incorporation), apoptosis (p53, Bax/Bcl,
and TUNEL), ECM composition (sulfated glycosaminoglycans [sGAG], collagen types I, II, and X,
and cartilage oligomeric matrix protein [COMP]), production of factors and proteins (BMP2, FGF2,
IHH, OCN, OPG, RANKL, PTHrP, Runx2, Sox9, TGF-β1, and VEGF-A), alkaline phosphatase
specific activity, and metabolism in cultures of growth plate chondrocytes and assessed
angiogenic activity in cultures of HUVEC cells. GC chondrocytes were transfected with microRNA
mimics, a corresponding microRNA inhibitor, and both together to validate target specificity of the
microRNA mimic and see if adding an inhibitor would begin to alleviate the effect of the microRNA
mimic. We analyzed ex vivo growth plate tissue in order to verify the presence of our target
microRNAs. This was accomplished by carefully isolating RC and GC regions of the growth plate,
removing all tissue and isolating the RNA. The RNA was analyzed using a multiplex microRNA
probe assay and RT-qPCR. These results were published in 2021 and are reprinted here in the
section “Specific MicroRNAs Found in Extracellular Matrix Vesicles Regulate Proliferation and
Differentiation in Growth Plate Chondrocytes”.
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Aim 2:
Determine the effect of 1α,25-dihydroxyvitamin D3 on the
composition of microRNAs in matrix vesicles and whether 1α,25dihydroxyvitamin D3 plays a role in the release of microRNAs by
matrix vesicles into the extracellular matrix.
GC chondrocytes were treated with 1α,25(OH)2D3 for 24 hours and the cells and MVs
isolated. The RNA was extracted from the isolations and submitted for small RNAseq. The
sequencing data were aligned and the reads analyzed for differential expression between the
various groups and the differentially expressed microRNA submitted for pathway and target
analysis. Isolated MVs were treated with 1α,25(OH)2D3 in the presence and absence of RNase
for three hours and the RNA isolated and analyzed for degradation. To assess endocytosis
isolated MVs were stained with a lipophilic membrane fluorophore, treated with vehicle or
1α,25(OH)2D3 and incubated with chondrocytes for 24 hours. The chondrocytes were treated with
a nuclear counterstain and fixed before imaging on a confocal microscope to determine the
percent of chondrocytes with bound MVs. These results are under review and are printed here in
the section “1α,25(OH)2D3 Regulation of MV MicroRNA”.
Aim 3:
Ascertain mRNA targets of select microRNA and the pathways
linking microRNA regulation to phenotypic changes.
Specific biotin tagged microRNA mimics were transfected into chondrocytes and
incubated for 48 hours. The chondrocytes were then lysed and RNA isolated using streptavidin
tagged magnetic beads. The isolated RNA was sequenced in house on a benchtop long read
sequencer. The resulting reads were aligned against the rat transcriptome and analyzed for
differential expression against the NC group. Up and down-regulated differentially expressed
genes between each of the five comparisons were examined for overlap and the 3` UTR
downloaded in order to predict the microRNA to mRNA binding energies. Differentially expressed
up-regulated genes were used for pathway analysis.
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Background
Growth Plate
Mammalian bone growth is driven by two types of ossification. Endochondral ossification
is responsible for long bone growth while intramembranous ossification primarily produces the flat
bones found in the skull.[10] Both processes stem from mesenchymal tissue with endochondral
ossification building upon a cartilaginous intermediate template – the growth plate – that is
mineralized and then replaced with bone.[11] In long bones and in the cartilage at the
costochondral junction of the ribs, the growth plate has a linear morphology and can be divided
into different zones populated by chondrocytes with distinct phenotypical characteristics.
Chondrocytes mature as they move through the growth plate forming into organized columns of
cells as they progress, passing from the resting or reserve zone through the proliferative zone,
the prehypertrophic zone, the hypertrophic zone and finally into the zone of calcification, which is
accompanied by capillary invasion.[12]
The linearity of the growth plate enables separation of the regions by sharp dissection.
Cells in the RC, located at the epiphyseal end of the growth plate in long bones, are less
differentiated and produce an ECM that is enriched in collagen type II and sGAG.[13,14] The GC
region contains cells in the lower proliferative cell zone, prehypertrophic chondrocytes, and the
upper hypertrophic cell zone, in which cells are undergoing terminal differentiation.[15] GC
chondrocytes can be characterized by increased levels of collagen type X, ALP, VEGF and
RANKL.[13,16–18] At the edge of the hypertrophic zone the vasculature begins to invade from
the bordering metaphysis marking the end of the growth plate.[19] This process of maturation is
precisely regulated by a complex interplay of growth factors, cytokines, and hormones, including
two metabolites of vitamin D, 1α,25(OH)2D3 and 24R,25(OH)2D3.[20–22]
One role of the growth plate is to provide a mechanism for tissue growth prior to
mineralized bone formation.[23] RC chondrocytes are surrounded by a proteoglycan-rich, nonmineralized ECM.[7,24] A subset of these cells align into columns and undergo a series of
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doublings, thereby increasing the overall length of the tissue. In the post-proliferative growth plate,
GC chondrocytes prepare the proteoglycan and type II collagen rich ECM for mineralization.[25]
This is a complex process requiring selective removal of proteoglycan aggregates, which inhibit
mineral formation via stearic hindrance as well as by limiting available Ca++ via interaction with
negatively charged sGAG.[17] Chondrocytes manage the process by synthesizing appropriate
ECM proteins and by releasing enzymes targeted to the specific removal of calcification inhibitors,
as well as by the release of cell zone-specific MVs.[25,26]
Matrix Vesicles
MVs have been isolated from the ECM of growth plate cartilage, as well as from other
calcifying tissues, including primary bone, fracture callus, and dentin.[27,28] MVs were first
observed via electron microscopy and found to be focal points for the calcification process and
have since been found to play an active role in matrix turnover and chondrocyte regulation.[29]
They have also been found at the epithelial/mesenchymal interface of calcifying neoplasias and
more recently, similar extracellular microsomes have been found associated with metastatic
cancers[30,31]
In the growth plate, MVs are small (50 – 150 nm in diameter) lipid bound organelles
anchored to collagen within the ECM.[19,32,33] They are produced by the chondrocytes but are
distinct from them with respect to their membrane phospholipid composition.[34,35] Their payload
consists of minerals, enzymes, factors, and microRNAs with distinct packaging dependent on
where in the growth plate they are produced.[2,9,36,37] MVs are enriched in acidic phospholipids,
particularly phosphatidylserine and phosphatidylinositol, which have been associated with initial
sites of Ca++ hydroxyapatite formation in tissues not previously calcified, such as the growth plate
and fracture callus.[38,39] MVs found in the ECM contain selectively enriched complements of
enzymes (e.g. TNAP, carbonic anhydrase, pyrophosphatase, PHOSPHO1, MMPs and their
inhibitors, etc.), as well as growth factors (e.g. BMP, VEGF), and other proteins including
osteopontin, all of which contribute to the mineralization process and subsequent bone
formation.[34,40–44] TNAP is an enzyme associated with calcification and considered a defining
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characteristic of MVs.[43] TNAP is anchored to the outer leaflet of the matrix vesicle membrane
via glycosylphosphatidylinositol.[45] Specific activity of this enzyme in matrix vesicles is greater
than twice that of the plasma membrane of the cells from which they were derived.[46]
MVs play an integral role in the mineralization process as centers for the start of
hydroxyapatite mineralization.[27,34,47,48] Initiation of calcification is generally considered to
take place in two distinct phases. As part of phase 1, 1α,25(OH)2D3 activates PDIA3 in MVs, which
stimulates PLA2 activity resulting in formation of lysophospholipids that stimulate PKCα activity
and destabilization of the MV membrane.[49] As the ATP content of the MV is depleted, the
concentration of Ca++ increases and Ca++ binds to phosphatidylserine forming calciumphospholipid-phosphate complexes, leading to the start of hydroxyapatite crystal formation on the
inner leaflet of the MV membrane.[19,50] Phase 2 involves MV membrane breakdown and
exposure of hydroxyapatite to extracellular Ca++ and inorganic phosphate, resulting in crystal
growth in the ECM.[30,47] MV phosphatases play an important role in this process by hydrolyzing
ATP, producing PPi. Pyrophosphatases in the MV hydrolyze PPi, releasing inorganic phosphate
thereby increasing the concentration of inorganic phosphate.[51] MV TNAP also acts on other
phosphorylated proteins and lipids in the ECM.[28] Mutations in the TNAP gene result in
hypomineralization in mice and the accumulation of pyrophosphates has been demonstrated to
reduce in vitro mineralization.[52–54]
Studies comparing MVs produced by RC chondrocytes and those produced by GC
chondrocytes show that they differ markedly.[55] They possess a different membrane
phospholipid composition; their alkaline phosphatase activity differs; and their matrix
metalloproteinase content differs. Whereas RC MVs contain primarily neutral metalloproteinases,
GC MVs are enriched in acidic metalloproteinases.[7] This implies that production of the
microsomes is under genomic regulation, but once in the matrix, control of their function must
involve non-genomic mechanisms, as they lack the machinery necessary for gene transcription
and protein synthesis.
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The importance of MVs to bone formation and cartilage maturation has become clearer
as our understanding of their regulatory potential expands. Over the years, researchers have
characterized MVs in increasing detail, focusing primarily on their role in calcification.[27] MVs
were found to contain genomic data in 1969 although it was not clear that the detected RNA had
a function or if it was potentially remnants from the cell that were unintentionally incorporated
during MV formation.[1] Small RNAs, including microRNA, have now been successfully
sequenced from MVs.[2] Their lifecycle and exact role in the growth plate is a central focus of this
work.
1α,25-dihydroxyvitamin D3
In vitro and in vivo studies in our lab have shown that vitamin D metabolites play a
significant role in the formation, content, and fate of MVs.[56] Two metabolites of vitamin D,
1α,25(OH)2D3 and 24R,25(OH)2D3 have different effects on MV composition that are specific to
the parent chondrocyte’s maturation zones in the growth plate.[7] RC cells respond primarily to
24R,25(OH)2D3, producing MVs that are enriched in neutral MMPs.[22] In contrast, GC
chondrocytes respond primarily to 1α,25(OH)2D3 and produce MVs that are enriched in acidic
MMPs.
MVs produced by both cell types possess receptors for 1α,25(OH)2D3, including the
canonical VDR and the membrane-associated receptor, PDIA3.[57,58] 1α,25(OH)2D3 acts on GC
chondrocyte plasma membrane associated PDIA3 to stimulate PKCα activity.[59] Although the
receptor for 24R,25(OH)2D3 is not yet known, this vitamin D metabolite also regulates PKC, but
only in RC cells and MVs.
The mechanisms by which these metabolites exert their modulation of MV PKCα is not
yet well understood but it appears to involve differential regulation of PLA2. The phospholipid
composition of the MV membrane differs, which may also play a role; PKCα is both Ca++ and lipid
dependent.[7] Particularly intriguing is the observation that both metabolites regulate MV
production in their respective target cells and stimulate inclusion of PKCζ.[59] PKCζ is not a Ca++dependent protein kinase, but why this isoform should be specifically incorporated is not yet
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known.[60] In the end 1α,25(OH)2D3 elicits an increase in PKC activity in GC chondrocytes and a
reduction in GC MVs while 24R,25(OH)2D3 produces an increase in PKC activity in RC
chondrocytes and a reduction in RC MVs.[60]
Chondrocytes are able to produce vitamin D metabolites under the regulation of growth
factors and hormones and secrete them into the ECM where they take part in regulating
MVs.[5,6,8] This suggests that control of ECM events by 1α,25(OH)2D3 and 24R,25(OH)2D3
produced locally is important to the overall management of growth plate development. Studies
examining regulation of TGF-β1 demonstrate this. Chondrocytes produce a number of TGF-β
related proteins, a superfamily that includes TGF-βs and BMPs as subfamilies.[61,62] Synthesis
and storage of TGF-β1 as latent TGF-β1 in the ECM is differentially regulated by the metabolites
on their target cells [8,63]. Activation of latent TGF-β1 stored in the ECM is regulated by MV
MMP3 and activation of latent TGF-β2 is regulated by MV MMP2, but this requires the direct
action of 1α,25(OH)2D3 on the MV membrane, resulting in formation of lysophospholipid and
release of the enzymes.[7,64] Active TGF-β1 binds to cellular membrane receptors, initiating a
signaling cascade,[62] that has a range of effects depending on the TGF-β1 concentration and
the cell type involved. TGF-β1 is able to regulate the enzymes involved in the metabolism of
25OHD3 in RC and GC cells as well as the maturation of growth plate chondrocytes.[7]
MicroRNAs stored in the MVs may be released into the ECM by a similar mechanism.
Lysophospholipids, produced by the action of PLA2 following binding of 1α,25(OH)2D3 to PDIA3
in the MV membrane, are naturally occurring detergents that have been shown to be able to both
activate TGF-β1 and release MMP-3.[65] Their detergent properties weaken the MV membrane,
resulting in the uptake of water and ultimately MV breakdown. Alternatively, released
lysophospholipids may modify the ECM, increasing access to MV enzymes.[7]
microRNA
MicroRNA are roughly 22 nucleotide long single-stranded non-coding RNA molecules that
play a role in the regulation of gene expression as part of the RISC.[66] RISC down-regulates the
transcription of specific messenger RNA or downright degrades them dependent on the level of
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complementarity the loaded microRNA strand has with the individual mRNA.[67,68] The scope of
microRNA’s role in regulating gene expression is still being elucidated although microRNAs are
being discovered in more and more places with some estimates claiming that microRNAs may
regulate over 1/3 of human genes.[2,69–72] microRNAs are understood to typically bind to the
three prime untranslated region (3′-UTR) of the mRNA strand (plants appear to disregard this
trend) using only a 6 to 8 base ‘seed region’ of the 22 base long miRNA.[72] microRNAs are
typically not restrained to an individual mRNA and multiple microRNAs can often regulate
individual mRNAs.[68]
MicroRNAs are able to impact the expression rates of mRNA within the cell and as a result
they are able to impact the expression of transcription factors within a cell. Modifying the
translation rates of transcription factors enables microRNAs to have a wide array of downstream
effects within the cell including the up or down-regulation of other microRNAs leading to the
potential for a type of microRNA network to exist within the cell.[73]
Selected microRNAs have been found to be concentrated within MVs[2]. Moreover, the
MV microRNA profile depends on the growth plate zone from which the parent chondrocytes have
been isolated. microRNAs 451-5p, 223-3p and 122-5p exhibit fold change increases in MVs
ranging from 25 to over 2,000 times what is observed in their respective parent cells, suggesting
a selective export and a role in growth plate regulation. These microRNAs have been examined
in other tissues. microRNA 451 reduces proliferation in human osteosarcoma cells; microRNA
223 reduces inflammation-based activation of macrophages; and microRNA 122 is a well-known
suppressor of hepatocellular carcinoma.[74–76] Effects of these microRNAs on chondrocytes and
the mineralization process are likely going to be somewhat unique as microRNAs typically are
able to impact the expression of multiple genes and the pathways impacted depend on the state
of the transcriptome. The differential content of the MVs reflects other differences in MV
composition (enzymes, lipid composition, membrane enzymes), which are also dependent on the
region of the growth plate where the MVs are produced.[7]
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Demonstration of MV microRNA composition is facilitated by the methods used to isolate
them. Whether isolating them from growth plate cartilage or from cultures of growth plate
chondrocytes, the process involves enzymatic digestion of the ECM, removal of cells and cell
fragments by differential centrifugation, and collection of the MVs from differential
ultracentrifugation of the trypsin digested ECM supernatant.[77] Efficiency of the isolation can be
verified by the enrichment of TNAP in the MV fraction compared to the cell plasma
membrane,[34,78] as well as absence of marker enzymes for various cell organelles.
A wide selection of microRNA target prediction tools is available, many with easy-to-use
web interfaces.[79–83] The tools are typically relying on a predictive algorithm to examine the
microRNA to mRNA binding within the 3` UTR of the mRNA and trying to predict what type of
stem and loop secondary structures will be present. These algorithms typically search for the
most energy advantageous location within the 3` UTR for a specific microRNA and use that MFE
value to predict the likelihood of mRNA regulation by the specific microRNA.[84–87] The
combination of algorithmic predictions and published research data results in putative lists of
target mRNA that number in the hundreds to thousands. Going from these lists to affected
pathways would require knowing the cell’s active transcriptome, factoring in the potential for
network, or secondary, microRNA effects and linking the resulting mRNA to active pathways
within the cell. Much of this information is not readily available for a given cell type and would
need to be confirmed by subsequent experimentation.
Differential Expression
Differential expression analysis is the standard first step when examining sequencing
datasets. Library preparation, polymerase chain reaction (PCR) bias, sample source, among
others, are all potential contributors to variation in read counts between samples.[88] This is
typically addressed using the normalization procedure included in the differential expression
software package (e.g. edgeR and DESeq2). DESeq2 was used for the analyses performed in
these studies and DESeq2’s median of ratios normalization procedure was implemented.
Isolations from cells had a 100 to 250 fold increase in total RNA when compared to the
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corresponding MVs. This large variation in RNA has the potential to bias the differential
expression analysis and skew the final results. A novel normalization procedure for this type of
data with very divergent samples could have broad usefulness for this and other studies. We
examined the six most exported microRNA in the initial study and verified the RNAseq results
with RT-qPCR. The confirmation of highly exported microRNA in MV samples that have
comparatively low starting quantities of total RNA using RT-qPCR provides reassurance that the
RNAseq analyses are valid.
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MicroRNA Contents in Matrix Vesicles Produced by
Growth Plate Chondrocytes are Cell Maturation
Dependent
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Plate Chondrocytes are Cell Maturation Dependent. Sci Rep 8, 3609 (2018).

Abstract
Chondrocytes at different maturation states in the growth plate produce MVs, membrane
organelles found in the extracellular matrix, with a wide range of contents, such as matrix
processing enzymes and receptors for hormones. We have shown that MVs harvested from GC
chondrocyte cultures contain abundant small RNAs, including miRNAs. Here, we determined
whether RNA also exists in MVs produced by less mature RC chondrocytes and, if so, whether it
differs from the RNA in MVs produced by GC cells. Our results showed that RNA, small RNA
specifically, was present in RC-MVs, and it was well-protected from RNase by the phospholipid
membrane. A group of miRNAs was enriched in RC-MVs compared RC-cells, suggesting that
miRNAs are selectively packaged into MVs. High throughput array and RNA sequencing showed
that ~39% miRNAs were differentially expressed between RC-MVs and GC-MVs. Individual RTqPCR also confirmed that miR-122-5p and miR-150-5p were expressed at significantly higher
levels in RC-MVs compared to GC-MVs. This study showed that growth plate chondrocytes at
different differentiation stages produce different MVs with different miRNA contents, further
supporting extracellular vesicle miRNAs play a role as “matrisomes” that mediate the cell–cell
communication in cartilage and bone development.
Introduction
Endochondral bone formation consists of a developmental cascade of chondrocyte
maturation that is well-regulated in temporal and spatial dimensions.[89] This is reflected in a
zonal change in cell morphology and function from resting to proliferative, prehypertrophic and
hypertrophic chondrocytes followed by calcification of the extracellular matrix, vasculogenesis,
and bone formation on the calcified cartilage scaffold. Central to the process of growth plate
development is the role of small membrane-bound extracellular microvesicles, called matrix
vesicles.[90] MVs are enriched in alkaline phosphatase specific activity compared to the plasma
membrane and the first calcium phosphate crystals are observed on the inner leaflet of the MV
membrane. Depending on the state of chondrocyte maturation within the growth plate, MVs have
a different phospholipid composition[91] and are selectively packed with different matrix
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metalloproteinases[35,44,92], alkaline phosphatase activity[91,93–95], growth factors[40], and
receptors for hormones[46,96,97], suggesting they function as regulators of the endochondral
bone formation environment[34,43,98].
We have established a cell culture model to study the phenotypic transition of
chondrocytes from the RC to the prehypertrophic/upper hypertrophic zone (GC), in which these
two cell types are cultured separately after discarding the intervening proliferative cell zone.[91]
Characterization of these two distinct cell populations has shown that they are different in
morphology[91], proliferation rate[91], extracellular matrix components[91], basal cation flux and
membrane fluidity[99–101], membrane phospholipid composition[91,101], basal production of
prostaglandin E2[102] and production of vitamin D metabolites 1,25-dihydroxyvitamin D3
[1,25(OH)2D3] and 24,25-dihydroxyvitamin D3 [24,25(OH)2D3][6].
In addition, RC and GC chondrocytes exhibit marked differences in their response to
vitamin D metabolites and growth factors[46,59,92]. Whereas RC cells respond primarily to 24
R,25(OH)2D3, GC chondrocytes respond primarily to 1α,25(OH)2D3. Testosterone stimulates
alkaline phosphatase specific activity in GC cells, with no effects on RC cells[103]; TGF-β1
induces a dose-dependent increase in proliferation of RC cells, but this effect was not seen in GC
cells[104]. Interestingly, even though RC chondrocytes will form nodules in long-term culture,
these cells do not mineralize their matrix. However, BMP2 or 24 R,25(OH)2D3 treatment of RC
cells induces a phenotypic shift into GC chondrocytes[105], which are able to calcify their
extracellular matrix.
Both types of chondrocytes produce MVs, but with distinctly different properties. MVs
produced by GC cells possess greater specific activities of alkaline phosphatase (the MV marker
enzyme)[91] and phospholipase A2 than do MVs produced by RC cells[101]. RC MVs contain
neutral metalloproteinases, whereas MVs produced by GC chondrocytes contain acidic matrix
metalloproteinases[35,92,102,106]. RC MVs also have different phospholipid profiles, membrane
fluidities and membrane receptors compared to MVs produced by GC cells[46,91,96,101]. PKC
activity in RC-MVs is regulated by 24 R,25(OH)2D3; however, it is stimulated by 1α,25(OH)2D3
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in GC-MVs[107,108]. RC-MVs are usually not able to calcify, however, mineralization occurs in
GC-MVs[109,110]. Taken together, these findings suggest that chondrocytes at different
maturation status in the growth plate produce different MVs with different contents, which
modulate their different local environment and satisfy different metabolic needs.
Recent studies show that microRNAs (miRNA), which are short (20–22-nucleotide),
endogenous, single-stranded, non-coding RNA molecules that regulate gene expression at the
post-transcriptional level[67], are involved in endochondral bone formation[111]. miR-145 was
downregulated during TGFβ3-induced chondrogenic differentiation of MSCs, and targeted Sox9
mRNA transcripts[112]. miR-140 was expressed in cartilage during embryonic development,
contributes to craniofacial development, and regulated HDAC4, but there was no evidence to
indicate its involvement in postnatal tissue[113]. miR-1 was shown to be specifically expressed in
the hypertrophic zone in postnatal growth plate, and repressed HDAC4[114]. These studies
substantiate the hypothesis that specific miRNA regulate growth plate cartilage.
miRNA is packaged in membrane bound vesicles termed endosomes, which are found in
biofluids such as blood, plasma, urine and saliva, as well as culture medium[115]. Emerging as
novel mediators in cell-cell communications, extracellular miRNA is involved in various
physiological and pathological processes[116]. Recently, our lab showed that small RNA, and
miRNA in particular, is highly enriched in matrix vesicles produced by GC chondrocytes[2].
Moreover, our results indicate that a group of miRNAs is selectively packed into these MVs,
suggesting that MVs function as “matrisomes,” providing a mechanism for information transfer in
the non-vascularized growth plate. However, it is not known whether small RNA also exists in
MVs produced by RC chondrocytes and, if so, whether there is difference in their miRNA
composition. The purpose of this study was to determine the presence of RNA in RC-MVs, and
then use PCR array and next generation sequencing to identify their miRNA profile. We also
compared the RC-MV miRNAs to those present in GC-MVs.
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Results
Characterization of RC-MVs.
Nanosight analysis showed that MVs isolated from RC chondrocyte cultures were
approximately 100 nm in diameter (Fig. 1.1 A). These vesicles demonstrated a more than 2-fold
increase in alkaline phosphatase specific activity compared to the RC plasma membrane, which
is a marker for MVs (Table 1.1). In addition, activity in RC-MVs was lower than in MVs from GC
chondrocyte cultures (Fig. 1.1 B), which exhibited a 6-fold enrichment over plasma membrane
activity (Fig. 1.1 C), being consistent with our previous observations[91].

A

B

C

Figure 1.1 Characterization of RC-MVs. (A) Nanosight was used to measure the size of RC-MVs, which
showed an average diameter around 80 nm. (B) Alkaline phosphatase (ALP) specific activity was
compared between RC-MVs and GC-MVs. GC cells produced MVs with higher ALP specific activity than
RC cells (n = 5 or 6). (C) In RC cell cultures, less ALP activity enrichment was seen in MVs compared to
that in GC cell cultures (n = 5 or 6). PM=plasma membrane.

Table 1.1 Alkaline phosphatase (ALP) specific activity of MVs from resting zone chondrocytes. Note: ap
< 0.05 compared with total cell lysate; bp < 0.05 compared with mitochondria; cp < 0.05 compared with
plasma membrane; dp < 0.05 compared with MVs; ep < 0.05 compared with pellet from culture medium;
n = 5 or 6. All the comparisons were done within the same cell type. (a–eBased on one way ANOVA). The
enrichment folds compared with total cell lysate are presented on the right.
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Small RNA is selectively packaged in matrix vesicles produced by resting zone
chondrocytes.
RC cells had both large ribosomal RNA (28 s and 18 s) and small RNA, while MVs
produced by these cells only exhibited small RNA that was less than 200 nt (Fig. 1.2 A). This was
confirmed by Bioanalyzer (Fig. 1.2 B). These RNAs were packed inside MVs and were protected
from enzymatic digestion by RNase. RNase treatment did not decrease the yield of RNA extracted
from MVs (Fig. 1.2 C). If the membrane was intact, RNase did not digest the MV RNA (Fig. 1.2
D). However, when Triton X-100 was added to disrupt the membrane, RNase completely digested
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Figure 1.2 RNA exists in RC-MVs. (A) MV RNA was compared to cell RNA. In a 2% agarose gel, RC-MV
RNA was heterogeneous in size but contained little or no large ribosomal RNA species (18S- and 28SrRNA) compared to parent cells. Enriched small RNAs were observed in MVs. (B) A similar pattern was
observed in the Bioanalyzer. (C) RC-MVs were treated by RNase A before RNA extraction by TRIzol. No
significant differences in the RNA:protein ratios of MVs with or without RNase pretreatment (n = 6) were
observed. (D) RNase was not able to digest the RNA component in MVs. However, it was able to digest
the total cell RNA. When the MVs were pre-treated with the membrane detergent Triton X-100, RNA
degradation was observed, suggesting that RNA in RC-MVs is protected by the intact lipid membrane.
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the RNA in the MV suspension. These results suggested that the RNA in the MVs was protected
by the phospholipid bilayer membrane.
Selective miRNAs are enriched in RC-MVs.
We used a PCR array to determine the miRNA profile of RC-MVs, and compared that to
the total cell miRNA profile. A distinct pattern was seen in RC-MVs with a selective group of
miRNAs that were highly enriched (Table 1.2). In this data set, 13 miRNAs were only detected in
RC-MVs but not RC-cells; 10 other miRNAs were found to have at least more than 2-fold
enrichment in RC-MVs, which included miR-150-5p, miR-126a-3p, and miR-129-2-3p.
Conversely, miRNA expression levels within the cells that were elevated compared to MVs
included miR-29b-3p, miR-503-5p, and miR-27a-3p. We also obtained a global view of RC-MV
small RNA using high throughput, unbiased RNA-Seq and compared the results to parent
chondrocytes (Fig. 1.3 A). The annotated small RNAs in RC-MVs included rRNA (20.55%),
transfer RNA (12.01%), miRNAs (6.08%), and non-coding RNA like snoRNA, Y_RNA, etc
(9.57%). In contrast, chondrocytes had significantly more miRNAs (10.54%).
When the RC-MV miRNA pool was examined more closely, we determined that it was
dominated by a small number of miRNAs. The most abundant miRNA in RC-MVs was miR-223p, which accounted for 20.27% of the total miRNA reads, followed by miR-21-5p (17.21%) and
miR-143-3p (11.77%). The top 3 most abundant miRNAs occupied over 50% of the miRNA pool
(Table 1.3), which was similar to that of the parent cell miRNA pool (Table 1.4). However, we also
found distinct differences in the miRNA profile between RC-MVs and RC-cells (Fig. 1.3 B). 139
(32.1%) miRNAs were found to be enriched in MVs by at least two-fold. The top 20 most RC-MV
enriched miRNAs (compared to RC-cells) identified from RNA sequencing are listed in Table 5.
We validated these findings using real time PCR.
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Table 1.2 miRNAs with different expression levels between RC-MVs and RC-cells in miRNA PCR array.
Note: miRNAs that were only detected in MVs from resting zone chondrocytes were shown in the left
column. miRNAs that were only detected in the resting zone chondrocytes were shown in the right column.
miRNAs that were detected both in resting zone MVs and cells, but with at least a 2-fold change and p <
0.05 were shown in the middle column. miRNAs that are in Italic area: highly enriched in RC MVs. miRNAs
that in underline area: mostly remained in RC cells. miRNAs highlighted in bold italic were selected for
further validation by RT-PCR.
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Figure 1.3 The profiles of small RNAs in RC-MVs and parent cells. (A) Complex populations of coding
and non-coding small RNAs were found in RC-MVs in proportions that were distinct from those in the RC
cells. (B) miRNAs in RC-MVs and RC-cells identified by RNA-seq were plotted. Red dots represent
miRNAs with at least a 2-fold expression level increase in MVs than those in cells. Green dots represent
miRNAs with more than a 2-fold expression level increase in cells than that in MVs. Blue indicates the
overlap between these two groups. A large number of miRNAs were differentially expressed between RCMVs and RC-cells.

6 RC-MV miRNAs (miR-451-5p, miR-223-3p, miR-122-5p, miR-142-3p, miR-150-5p, miR-126a3p) were selected because they were only detected or were highly enriched in RC-MV based on
the PCR-array (Table 1.2, highlighted in bold). We confirmed that these miRNAs were expressed
at significantly higher levels in RC-MV compared to RC-Cell (Fig. 1.4), suggesting that the
packaging of miRNAs into resting zone chondrocyte matrix vesicles is a selective process.
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Table 1.3 Top 20 most abundant miRNAs in
RC-MV

Table 1.4 Top 20 most abundant miRNAs in
RC-cells.

Table 1.4 Top 20 selectively packaged miRNAs in MVs in RNA
sequencing.
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Figure 1.4 Validation of the miRNA enriched in RC-MVs compared with parent cells. Six miRNAs (miR451-5p, miR-223-3p, miR-122-5p, miR-142-3p, miR-150-5p, miR-126a-3p) were selected for RT-qPCR
assays. Consistent with previous array results, the expression of all these miRNAs were significantly
higher in MVs compared to cells. These results suggest that certain miRNAs are selectively exported into
MVs. *p < 0.05 in t-test. **p < 0.01 in t-test. ****p < 0.0001 in t-test (n = 3).

Functional annotation of RC-MV enriched miRNAs.
miRNAs function by binding to target mRNAs and inhibiting their translation or promoting
degradation. We identified the target genes of the top most enriched miRNA in RC-MVs and
analyze the signaling pathways that are potentially involved. Based on results from KEGG
signaling pathway analysis, key functions of target genes included roles in stem cell regulation,
Hippo signaling, Wnt signaling, Rap1 signaling, ErbB signaling, focal adhesion, and cell cycle,
many of which have been shown to be involved in chondrocyte proliferation and differentiation
(Table 1.6).
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Table 1.6 KEGG pathways targeted by the top 10
RC-MV enriched miRNAs.

MV miRNA component is dependent on the cell maturation status.
We have previously shown distinct differences in MVs that can be ascribed to the level of
chondrocyte maturation. We recently reported that GC-MVs were packed with selective miRNAs.
Based on these studies, we hypothesized that miRNAs were selectively packed into RC and GC
MVs. To investigate unique maturation-dependent differences, we compared the PCR array
results of RC-MVs to those of GC-MVs. In the 182 miRNAs detected, 10 miRNAs were identified
in GC-MVs and 7 were found in RC-MVs (Fig. 1.5 A). 35 miRNAs were differently expressed
between RC-MVs and GC-MVs with at least a more than 2-fold difference (increase or decrease)
(Table 1.7). We also identified a group of miRNAs that showed different expression levels
between RC cells and GC cells (Table 1.8). Using principle component analysis, we observed
differences between RC-MVs (purple dots, top left) and GC-MVs (green dots, bottom left) (Fig.
1.5 B). While 39% of miRNAs showed differential expression level with more than 2-fold difference
between RC-MVs (green dots, circled) and GC-MVs (red dots, circled), we observed a unique
separation between these miRNA (Fig. 1.5 C), further supporting our hypothesis. Therefore, the
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selective packaging of miRNAs into MVs exhibits spatial and maturation dependence.
Interestingly, less miRNAs were found differentially expressed between RC-cells and GC-cells
than between RC-MVs and GC-MVs (Fig. 1.5 C), suggesting more heterogeneous miRNA profiles
exist in the extracellular vesicles than that in the cytoplasm. It is worth mentioning that the
difference between RC-MVs and GC-MVs was less dramatic than between RC-MVs and RC-cells
or between GC-MVs and GC-cell, since the distance at the x-axis represents the most prominent
difference followed by the distance at the y-axis. This indicates that the difference between MVs
and the cells that produce them is more significant than that between two cell maturation statuses
(RC vs. GC) (Fig. 1.5 C).

A

B

C
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Figure 1.5 Distinct differences in the miRNAs between RC-MVs and GC-MVs. (A) Different miRNAs
patterns were identified from PCR-array between two maturation status of chondrocytes, both in MVs and
the parent cells. (B) Principal component analysis (PCA) of the miRNA PCR-array data for all the four
different types of samples: RC-MVs, RC-cells, GC-MVs and GC-cells. The differences among these
samples were clear, as larger difference showed on the x-axis direction compared to that on the y-axis.
This suggests that the differences between MVs and cells were larger than between two different cell
maturation stages. (C) Left panel: miRNAs in RC-MVs and GC-MVs identified by RNA-seq were plotted.
Red dots represent miRNAs with at least a 2-fold expression level increase in GC-MVs than in RC-MVs.
Green dots represent miRNAs with a more than 2-fold expression level increase in RC-MVs than in GCMVs. Blue indicates the overlap between these two groups. A large number of miRNAs were differentially
expressed between RC-MVs and GC-MVs. Right panel: similar comparison was done between RC-cells
and GC-cells. Interestingly, the difference between RC-cells and GC-cells was not as large as that was
seen between RC-MVs and GC-MVs.

To further validate our observations in miRNA PCR-array and RNA-Seq, we selected a
set of miRNAs that are highly expressed in RC-MVs and performed RT-qPCR to compare their
expression levels between RC-MVs and GC-MVs. Although we did not observe significant
differences in some of the selected miRNAs such as miR126a-3p and miR-451-5p, higher
expression levels of miR-122-5p and miR-150-5p were consistently seen in RC-MVs compared
with GC-MVs (Fig. 1.6). This further suggests that cells at different maturation status produced
different matrix vesicles with different miRNA contents.
Discussion
In this study, we demonstrate that RNA exists in MVs produced by costochondral growth
plate resting zone cartilage cells. This RNA is packaged by the cells within the extracellular
matrisomes and is protected by the MV membrane. RNase treatment of intact RC MVs didn’t
digest their RNA component, however significant degradation occurred after the membrane was
disrupted by Triton X-100. Moreover, a set of miRNAs was specifically enriched in the MVs, further
supporting the hypothesis that their inclusion involves a regulated process.
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Table 1.7 miRNAs with different expression levels between RC-MVs and GC-MVs in miRNA PCR array.
Note: miRNAs that were only detected in MVs from RC were shown in the left column. miRNAs that were
only detected in MVs from GC were shown in the right column. miRNAs that were detected in MVs from
both RC and GC cells, but with at least a 2-fold change and p < 0.05 were shown in the middle column.
miRNAs that are bold area: highly enriched in RC-MVs. miRNAs that in underline area: mostly enriched
in GC-MVs.
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Table 1.8 miRNAs with different expression levels between RC-cells and GC-cells in miRNA PCR array.
Note: miRNAs that were only detected in RC cells were shown in the left column. miRNAs that were only
detected in GC cells were shown in the right column. miRNAs that were detected in cells from both RC
and GC, but with at least a 2-fold change and p < 0.05 were shown in the middle column. miRNAs that
are in bold area: highly enriched in RC-cells. miRNAs that in underline area: mostly enriched in GC-cells.

Figure 1.6 RT-qPCR was used to further validate the differences in miRNA expression between RC-MVs
and GC-MVs. miR-122-5p and miR-150-5p had significantly higher expression levels in RC-MVs than
GC-MVs, suggesting the miRNAs contents in MVs are associated with the cell maturation status. **p <
0.01 in t-test. (n = 6).

A variety of RNA species were found in RC-MVs, similar to RNA species found in MVs
produced by GC chondrocytes[2]. The majority of the RNA pool in RC-MVs was rRNA and tRNA.
It is still not clear the biological meaning of these RNAs in the regulation of extracellular matrix
and cell behavior. Recently, it was reported that tRNAs can be cleaved into small fragments that
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can also function as miRNAs[117]. Despite these similarities, however, PCR array and RNA-Seq
showed that a large group of miRNAs was differentially expressed in MVs from RC and GC cells.
Individual RT-PCR confirmed that there were significant differences in some miRNAs, such as
miR-122-5p and miR-150-5p.
Chondrocytes at different maturation states in the growth plate not only produce zonespecific extracellular matrix[91,118–120], but as noted above, their matrix vesicles differ in
phospholipid profile[91], enzyme content[35,91,92], and response to hormones[46,102,108]. Our
results add to this by demonstrating maturation-dependent differences in miRNA composition.
This suggests that MV miRNAs may be involved in the regulation of zone-specific phenotypic
behavior of the cells. Our previous observation that release of matrix vesicle contents is mediated
by regulated secretion of 1α,25(OH)2D3 and 24R,25(OH)2D3 and their interaction with the MV
membrane[7,8,92,121], provides a mechanism for modulating the bioavailability of the miRNAs
during endochondral development.
The relative differences between miRNA in RC and GC cells and the differences between
RC-cells and RC-MVs or GC-cells and GC-MVs were greater than the differences between RCMVs and GC-MVs. Chondrocytes in the resting zone of the growth plate will eventually express a
growth zone phenotype, so it is likely that the phenotypic shift involves only a subset of
components. MV species are heterogeneous[122], so it is also possible that not all MVs are
uniformly modulated during growth plate development.
Further investigation is needed to determine whether there are general properties that
define matrisomes or if they are tissue or cell specific. Others have reported the presence of RNA
in the extracellular matrix of mineralizing tissues[1], and miRNAs have been found in dermis,
bladder and small intestinal submucosa, which are associated with extracellular matrix-bound
nanovesicles[123]. Compared to other extracellular vesicles such as exosomes, MVs are unique
in many ways. MVs have a strong affinity to collagen and stay in the extracellular matrix, while
exosomes are released into the culture media[2,91]. The biogenesis mechanisms of MVs and
exosomes are different as well. MVs are formed by a cell “budding” mechanism, but exosomes
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are formed through membrane invagination[124]. MVs released by resting zone and growth zone
chondrocytes also express higher alkaline phosphatase activity than the plasma membrane and
compared to membrane vesicles they secrete into the medium[91]. Furthermore, the
heterogeneity of matrix vesicles produced by chondrocytes[122], indicates that they may perform
multiple functions in the extracellular matrix. A recent study also found that mesenchymal stem
cells secret at least three different types of microvescicles with different RNA material[125], raising
the possibility that miRNAs may be differentially packaged in subsets of matrisomes and
exosomes to modulate specific cell functions.
Extracellular miRNAs, exosomal miRNAs in particular, have been shown to play an
important role in cell–cell communication in physiological and pathological processes[116].
Similarly, MV miRNAs may also function as a modulator during chondrogenesis by transferring to
other cells in the local environment in an autocrine or paracrine manner, and thereby, regulating
their gene expression and biological behavior. Functional analysis suggests that MV miRNAs are
associated with stem cell regulation. miR-122-5p, which has been related to liver function and
HCV infection[126], was more highly expressed in RC-MVs than GC-MVS. Others have shown
that miR-122-5p targets the IGF-1R signaling pathway, which is a major player in the
musculoskeletal system[127]. Our preliminary data showed that overexpression of miR-122-5p
enhanced chondrocyte proliferation and maintained the stemness of these cells (data not shown).
miR-150-5p,

which

is

also

higher

in

RC-MVs

was

reported

to

target

matrix

metalloproteinases[128,129]. Therefore, RC-MV enriched miRNAs may help maintain the local
environment needed for RC cells to maintain a stronger proliferative capability than GC cells.
In conclusion, we demonstrated that RNA is present in MVs derived from resting zone
chondrocytes, and selective miRNAs are enriched. We also observed that miRNAs are
differentially expressed between RC-MVs and GC-MVs, although these differences are not as
prominent as those between RC-MVs and RC-cells. Our results further suggest the importance
of extracellular matrix RNA during chondrogenesis and endochondral bone formation.
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Methods
Chondrocyte cultures.
Chondrocytes were isolated by enzymatic digestion of the costochondral cartilage of 125
g male Sprague Dawley rats and cultured as described by Boyan et al. previously[91]. All
procedures conducted on animals followed a protocol approved by the Institutional Animal Care
and Use Committee (IACUC) at Virginia Commonwealth University, and all experiments were
performed in accordance with relevant guidelines and regulations. Rib cages were removed and
placed in Dulbecco’s modified Eagle’s medium (DMEM, Life Technologies). The resting zone and
growth zone cartilage was carefully dissected out, sliced, and incubated in 1% trypsin (Life
Technologies) for 1 hour and 0.02% collagenase for 3 hours. After filtering by 40-micro nylon
mesh, cells were collected by centrifugation, resuspended in DMEM, and plated at a density of
25,000 cells/cm2. Fetal bovine serum (FBS, Life Technologies) was centrifuged at 184,000 × g
for 4 h to remove the bovine serum exosomes. Chondrocytes were incubated in DMEM containing
10% exosome-free FBS, 1% penicillin/streptomycin and 50 mg/ml ascorbic acid (Sigma-Aldrich).
Cell culture medium was changed 24 hours after plating and then at 72-hour intervals. At
confluence (5–7 days), cells were subcultured using the same plating densities and allowed to
return to confluence. All experiments used confluent cells in their fourth passage.
MV isolation and characterization.
MVs were isolated from chondrocyte cultures by differential centrifugation of the trypsin
digested cell layer, as described in detail previously[91]. Briefly, after trypsinization (0.25%
Trypsin-EDTA, Life Technologies) for 10 min, 1 × DPBS containing 10% exosome-free FBS was
added to stop the reaction. The MVs were isolated by sequential centrifugation at 500 g for 5 min,
21,000 g for 20 min, and 184,000 g for 70 min. The MV pellets were washed with 0.9% NaCl and
recentrifuged at 184,000 g for 70 min. The same centrifugation protocol was used to pellet the
microvesicles in cell culture media. Alkaline phosphatase specific activity was measured and
normalized to protein content. In addition, to validate that MVs were isolated but not plasma
membrane debris, plasma membranes were isolated from the cell pellet as described previously
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and alkaline phosphatase activity determined. Alkaline phosphatase specific activity was enriched
in MVs at least 2 folds compared to plasma membrane, which was consistent with our previous
studies. The original MVs solution was diluted 200 times for nanoparticle tracking analysis
(Nanosight, Malvern, UK).
RNA extraction and detection.
RNA was isolated from MVs or cells using TRizol (Life Technologies). RNA was eluted
with RNase-free water and quantified by NanoDrop spectrophotometer (Thermo Scientific). For
agarose gels, 100 ng RNA was run and visualized on a 2.2% agarose gel FashGelTM System
(Lonza). Bioanalyzer analyses were performed using 300 ng RNA with an RNA 600 Nano Kit
(Agilent) and an Agilent 2100 Bioanalyzer (Agilent) according to manufacturer’s protocol. To
confirm that RNA was inside and not outside the MVs, the vesicles were treated with RNase A
(10 mg/ml, Qiagen) before RNA extraction as described previously[2]. MVs were also incubated
with 0.05% Triton-X 100 in order to break down the membrane in some experiments.
miRNA PCR profiling in MVs.
cDNA library preparation and miRNA profiling were performed in MV and cell RNA from
RC and GC chondrocytes as described previously[2]. The microRNA PCR array (miRCURY LNA
Universal RT microRNA PCR array) included 223 rat miRNAs. Details in data normalization and
analysis were provided in supplementary materials.
Reverse transcription and quantitative real-time PCR (RT-qPCR).
50 ng RNA was reverse transcribed to cDNA with miScript II RT kit (Qiagen), followed by
real-time qPCR using the StepOnePlus Real-time PCR System and miScript SYBR Green PCR
Kit (Qiagen). Fluorescence values were quantified as starting quantities using known dilutions of
standard control. The reverse primer was the universal primer in the kit. The sequences for the
forward

primers

were

synthesized

by

Eurofins

MWG

Operon:

rno-miR-451-5p:

AAACCGTTACCATTACTGAGTT; rno-miR-223-3p: TGTCAGTTTGTCAAATACCC; rno-miR122-5p: TGGAGTGTGACAATGGTGTT; rno-miR-142-3p: TGTAGTGTTTCCTACTTTATGGA;
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rno-miR-150-5p:

TCTCCCAACCCTTGTACCAGT;

rno-miR-126a-3p:

TCGTACCGTGAGTAATAATGCG; rno-miR-652-3p: AATGGCGCCACTAGGGTT.
RNA sequencing (RNA-Seq).
RNA was isolated from MVs or cells using TRizol. Next generation sequencing was
performed in an Illumina HiSeq. 2500 (Illumina, San Diego, CA). Data normalization and analysis
were conducted with the miARma-Seq tool (see supplemental materials). Briefly, sequence
quality was assessed with FASTQC; sequence reads were aligned with Bowtie2 to the NCBI
Rattus norvegicus annotation release 105 (Rnor_6.0). The resulting bam files were used by
miARma-Seq for tabulating discovered miRNA. Reads were also aligned to Rfam 12.3 with
Bowtie2 for categorization of RNA reads. To quantify the differential expression of miRNA
between samples, the count of each miRNA was normalized as the percent of all discovered
miRNAs in that sample. The fold-change was calculated as the percent expression of MV
miRNA/Cell miRNA. KEGG Pathway enrichment analyses were performed based on the target
genes of selected miRNAs.
Statistical analysis.
Alkaline phosphatase specific activity is presented as mean ± standard error of the mean
(SEM) for 6 independent MV samples per variable. RT-qPCR is presented as mean ± SEM for 3
independent samples per variable. Data were examined by ANOVA with post-hoc Bonferroni’s
modification of Student’s t-test. A p value of less than 0.05 was considered statistically significant.
Statistical analyses for miRNA array and RNA-Seq data were performed according to our previous
protocol[2].
Data availability statement.
The datasets generated during the current study have been submitted to NCBI GEO
database (GSE106348).
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Supplementary materials

RC Cell

RC MV

Next generation RNA sequencing
RNA was isolated from MVs or cells using TRizol. Next generation sequencing was
performed in an Illumina HiSeq 2500 (Illumina, San Diego, CA). Data normalization and analysis
were conducted with the miARma-Seq too (Andres-Leon, E. et al, 2016). Briefly, sequence quality
was assessed with FASTQC; sequence reads were aligned with Bowtie2 to the NCBI Rattus
norvegicus annotation release 105 (Rnor_6.0). The resulting bam files were used by miARmaSeq for tabulating discovered miRNA. Reads were also aligned to Rfam 12.3 with Bowtie2 for
categorization of RNA reads. To quantify the differential expression of miRNA between samples,
the count of each miRNA was normalized as the percent of all discovered miRNAs in that sample.
The fold-change was calculated as the percent expression of MV miRNA/Cell miRNA. KEGG
Pathway enrichment analyses were performed based on the target genes of selected miRNAs.
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Specific MicroRNAs Found in Extracellular Matrix
Vesicles Regulate Proliferation and Differentiation in
Growth Plate Chondrocytes

Asmussen, N.C., Cohen, D.J., Lin, Z. et al. Specific MicroRNAs Found in Extracellular Matrix
Vesicles Regulate Proliferation and Differentiation in Growth Plate Chondrocytes. Calcif Tissue
Int 109, 455–468 (2021).

Abstract
MVs are extracellular organelles produced by growth plate cartilage cells in a zonespecific manner. MVs are similar in size to exosomes, but they are tethered to the ECM via
integrins. Originally associated with matrix calcification, studies now show that they contain matrix
processing enzymes and microRNA that are specific to their zone of maturation. MVs produced
by costochondral cartilage RC chondrocytes are enriched in microRNA 503-5p whereas those
produced by GC chondrocytes are enriched in microRNA 122-5p. MVs are packaged by
chondrocytes under hormonal and factor regulation and release of their contents into the ECM is
also under hormonal control, suggesting that their microRNA might have a regulatory role in
growth plate proliferation and maturation. To test this, we selected a subset of these enriched
microRNAs and transfected synthetic mimics back into RC and GC cells. Transfecting growth
plate chondrocytes with select microRNA produced a broad range of phenotypic responses
indicating that MV-based microRNAs are involved in the regulation of these cells. Specifically,
microRNA 122-5p drives both RC and GC cells towards a proliferative phenotype, stabilizes the
matrix and inhibits differentiation whereas microRNA 22-3p exerts control over regulatory factor
production. This study demonstrates the strong regulatory capability possessed by unique MV
enriched microRNAs on growth plate chondrocytes and their potential for use as therapeutic
agents.
Introduction
MVs are small membrane bound organelles present in the ECM of mammalian growth
plates, as well as other calcifying tissues including dentine, metastatic cancers, and blood
vessels.[30,31]

Like exosomes, they range in size from roughly 50 to 150 nm. Whereas

exosomes are found in biological fluids, MVs are tethered to the ECM via integrins.[43,130] Long
associated with matrix calcification,[29,34,131] studies show that MVs also play a role in growth
plate regulation.[34,36] Their importance in the avascular growth plate is related to their contents,
which vary with the zone of chondrocyte maturation. MVs produced by RC cartilage cells are
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enriched in neutral metalloproteinases needed for maintenance of a proteoglycan rich
matrix.[36,37,132]

In

contrast,

MVs

produced

by

GC

cartilage

cells

contain

acid

metalloproteinases, which are involved in matrix degradation prior to matrix calcification.[35–37]
Recently, studies have demonstrated that microRNAs are selectively packaged inside
these MVs in both the RC and GC regions of the costochondral cartilage growth plate, with 37%
of the MV microRNA significantly increased or decreased compared to cell microRNA.[2,55]
Further examination showed that 22% of the microRNA in RC MVs are differentially expressed
when compared to GC MVs.[55] This suggests that MV microRNA may also function in the
regulation of growth plate chondrocyte proliferation, differentiation and maturation.
The costochondral cartilage growth plate provides an excellent model for assessing the
role of individual microRNA in this process. Growth plate chondrocytes express phenotypic
changes as they mature with corresponding alterations in the composition of the ECM. Within the
costochondral cartilage growth plate the RC encompasses the reservoir of immature
chondrocytes and the upper proliferative zone. Cells in the lower proliferating zone, pre and upper
hypertrophic zones are referred to as GC chondrocytes. RC and GC chondrocytes can be
successfully cultured and retain unique phenotypes through four passages as well as exhibiting
zone-specific responses to regulatory factors and hormones.[8,91,133,134]
Various factors are involved in growth plate regulation. We selected a handful of the key
regulators, described here in greater detail, to investigate if their production is affected by select
microRNA transfection. Ihh and PTHrP are two factors that form a feedback loop regulating the
proliferation and differentiation of chondrocytes at various stages of the growth plate.[135–137]
Resting chondrocytes at the periarticular end of the fetal lone bone growth plate express PTHrP
that, in turn, maintains chondrocytes in a proliferative state, delaying their differentiation to
hypertrophic cells.[11,138] As chondrocytes move far enough away from the PTHrP production
they stop proliferating and begin to express Ihh, marking the transition within the growth plate
from proliferating to hypertrophic chondrocytes.[11,136] This Ihh diffuses through the growth plate
and stimulates continued PTHrP production in the resting chondrocytes. This feedback loop
Asmussen | MicroRNA in the Mammalian Growth Plate: Matrix Vesicles and 1α,25-Dihydroxyvitamin D3

51

functions to regulate the distance between PTHrP and Ihh expressing zones, providing sufficient
space for the proliferating chondrocytes.[137]
Additional factors are known to play important roles in regulating the growth plate. TGFβ1 stimulates bone marrow stromal cell differentiation and regulates chondrocyte maturation.[139]
VEGF is produced by hypertrophic chondrocytes and is involved in the vascular invasion that
occurs in the late hypertrophic region.[16,137,140] Sox9 is an early transcription factor active
during chondrocyte differentiation and required for the expression of specific matrix
proteins.[141,142] RUNX2 is involved in late stage chondrocyte differentiation and needed for the
expression of numerous proteins.[143]
This study examines the role that MV microRNA may be playing in the regulation of growth
plate chondrocytes. We hypothesize that the microRNAs exported with the highest fold change
by GC chondrocytes likely play distinct roles in proliferation, differentiation, factor production and
ECM composition of cells in the upper growth plate as well as the zone of maturation. Accordingly,
we report on the effect that a select subgroup of GC MV microRNAs have on both RC and GC
chondrocytes.
Results
Where an effect from treatment was observed it is in relation to the negative control (NC)
microRNA group. Unlike the no treatment (NT) group, NC received transfection reagents and a
scrambled vector microRNA.
MicroRNA Expression
Comparing the differentially expressed microRNAs in GC MVs vs. cells using a stacked
bar chart we were able to identify the microRNAs exhibiting the largest fold change (Fig. 2.1 A).
We selected microRNA 22-3p as a positive control due to its abundance in the cell fraction (2.2%)
compared to the top three MV microRNA (≤ 0.0005 %) and its similar expression profile in RC
samples (Fig. 2.1 B). We selected the three microRNA (122-5p, 223-3p and 451-5p) having log2
fold change values below -10 (Fig. 2.1 C).
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Nanostring analysis using a panel of rat microRNA showed that microRNA 22-3p was
present in high proportion for both RC and GC sections. MicroRNA 122-5p and 223-3p were not
above background levels in either RC or GC samples and microRNA 451-5p was only found
above background in the GC samples (Fig. 2.1 D). MicroRNA not above background levels are
those that are at or below the threshold levels determined by the system for each sample.

Figure 2.1 MicroRNA expression of resting zone (RC) and growth zone (GC) cells. (A) Differentially
expressed microRNAs (FDR < 0.05) found in MVs as compared to cell isolate. (B) Expression of select
four microRNA in RC and GC samples based on normalized read counts from EdgeR. (C) Volcano plot
of microRNA in GC cells compared to MVs, red denotes differentially expressed microRNA with FDR <
0.05, teal are not differentially expressed. (D) Nanostring analysis of RC and GC ex-vivo tissue samples,
minimum threshold levels determined by Nanostring system. (E) MicroRNA RT-qPCR cycle threshold
values for RC and GC ex-vivo tissue samples. Mean ± SE.

MicroRNA RT-qPCR on RC and GC tissue samples had CT values below 35 for snRNA
U6 and microRNA 22-3p. MicroRNA 122-5p and 451-5p groups had three out of four GC samples
below 35, all RC samples were between 35 and 40 but one in 451-5p group that was above 40
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(Fig. 2.1 E). For microRNA 122-5p the standard curve stopped amplifying at 0.06 ng/μL and for
microRNA 451-5p amplification was no longer detected at 0.02 ng/μL with a total cycle count of
60. Examining the melt curves for all eight groups shows tight clustering and a peak appearing
within or near to the expected Tm range of 74.5-76˚C for these primers (Supplemental Fig. 2.1).
Response of GC Chondrocytes
Chondrocyte Proliferation and Apoptosis
MicroRNA 122-5p increased total DNA at 24 and 48 hours while microRNA 451-5p
decreased it. MicroRNA 22-3p and 223-3p had no effect at 24 hours whereas at 48 hours
microRNA 22-3p decreased and microRNA 223-3p increased total DNA (Fig. 2.2 A,B). We
normalized microRNA treatments to controls for 12 separate experiments and observed a
consistent increase in DNA production as a result of microRNA 122-5p while being unaffected by
microRNA 22-3p, 223-3p or 451-5p (Fig. 2.2 C). We examined proliferation rates using EdU
incorporation at 24 and 48 hours. MicroRNA 122-5p and 451-5p increased the proliferation rate
at 24 hours while all four microRNAs increased proliferation at 48 hours (Fig. 2.2 D,E). We
examined whether the acute impact of microRNA 122-5p on proliferation was present at earlier
time points. MicroRNA 122-5p increased proliferation at 0, 12 and 24 hours compared to NC after
which it fell below NC for 36 and 48 hours (Fig. 2.2 F). Examining metabolic activity, there was
increased MTT reduction in GC cells transfected with microRNA 122-5p at 48 hours (Fig. 2.2 G).
None of the select microRNA appeared to induce cellular apoptosis. No change was
observed between NC and any of the microRNAs with TUNEL (DNA fragmentation) (Fig. 2.2 H),
Bax / Bcl2 levels (Fig. 2.2 I) or p53 levels (Fig. 2.2 J).
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Figure 2.2 Proliferation and apoptosis of GC cells. (A, B) Total DNA at 24 & 48 hrs. (C) Treatment over
control of total DNA at 48 hrs for twelve experiments. (D, E) Proliferation rate at 24 & 48 hrs, (F) time
course every 12 hrs for 48 hrs. (G) Metabolism of GC cells at 48 hrs. (H–J) Apoptosis indicators (Tunnel,
Bax / Bcl2 ratio and p53) were assayed at 48 hrs. Mean ± SE, groups not sharing a letter are statistically
different (α = 0.05), NT: no treatment, NC: negative control microRNA.

Alkaline Phosphatase Activity and ECM Composition
Chondrocytes demonstrated an increase in alkaline phosphatase activity in response to
microRNA 223-3p with 122-5p and 451-5p having a significant reduction compared to NC (Fig.
2.3 A). Looking at 5 separate experiments confirmed these results with microRNA 223-3p
increased compared to NC and microRNA 122-5p and 451-5p decreased (Fig. 2.3 B).
Production of two ECM components – sGAGs and collagen 2 – was sensitive to microRNA
transfection. MicroRNA 122-5p increased sGAG levels compared to all other groups while
decreasing levels of collagen 2 (Fig. 2.3 C,D). Collagen X was also examined and found to be
below the standard for all samples (data not shown).
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GC

Figure 2.3 Alkaline phosphatase activity and ECM composition of GC cells. (A, B) Alkaline phosphatase
activity of GC cells at 48 hrs & treatment over control of five experiments. (C, D) sGAG & collagen 2
production by GC cells. Mean ± SE, groups not sharing a letter are statistically different (α = 0.05), NT:
no treatment, NC: negative control microRNA.

Growth Plate Factors
Seven different ELISAs were used to investigate the production of growth plate proteins
(BMP-2, Ihh, OPG, PHTrP, RANKL, TGF-β1 and VEGF) with protein levels normalized to total
DNA per well. BMP-2 was below the standard for all samples (data not shown). VEGF increased
following microRNA 22-3p transfection and decreased in response to microRNAs 122-5p and
451-5p (Fig. 2.4 A). OPG production increased in response to microRNA 122-5p or 451-5p, while
RANKL was not detected in any of the samples (Fig. 2.4 B,C). GC cells exhibited an increase in
Ihh and PTHrP production following microRNA 22-3p and a decrease following microRNA 1225p (Fig. 2.4 D,E). Transfected chondrocytes increased latent TGF-β1 as a response to microRNA
22-3p compared to the control cultures, but levels were not different than NT and no change in
active TGF-β1 was observed (Fig. 2.4 F,G).
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Figure 2.4 Growth plate factor production of GC cells at 48 hrs (A) VEGF, (B) OPG, (C) RANKL, (D) Ihh,
(E) PTHrP, (F) Active TGF-β1 and (G) Latent TGF-β1. Mean ± SE, groups not sharing a letter are
statistically different (α = 0.05), NT: no treatment, NC: negative control microRNA.

Response of RC Chondrocytes
Proliferation and Apoptosis
Total DNA, TUNEL and p53 of RC chondrocytes were assessed at 48 hours. Total DNA
increased in cells following microRNA 122 transfection whereas it was decreased by microRNAs
22-3p, 223-3p and 451-5p (Fig. 2.5 A). Apoptosis as measured by TUNEL and p53 was unaffected
by the four microRNAs (Fig. 2.5 B,C).
Alkaline Phosphatase Activity and ECM Composition
RC chondrocytes exhibited a reduction in alkaline phosphatase activity for all four
microRNA when compared to control with microRNA 122 resulting in a significantly greater
decrease (Fig. 2.5 D). We normalized the five microRNA treatments over control (NT) for three
separate experiments at 48 hours and observed a similar response (Fig. 2.5 E). ECM composition
was assessed by sGAG levels with microRNA 22-3p resulting in a decrease in sGAG levels and
microRNA 122-5p an increase (Fig. 2.5 F).
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Growth Plate Factors
Ihh and PTHrP were found to be increased as a result of microRNA 22-3p transfection
and decreased following transfection with microRNA 122-5p (Fi g. 2.5 G,H).
Selective microRNA Inhibitors
In order to examine the sensitivity of the mimics used in the transfection experiments, RC
and GC chondrocytes were transfected with a select microRNA inhibitor (22-3p or 122-5p) at

Figure 2.5 Response of RC cells at 48 hrs. (A) Total DNA quantity, (B, C) apoptosis indicators TUNEL &
p53. (D) Alkaline phosphatase activity of RC cells and (E) treatment over control for three experiments.
(F) sGAG production of RC cells. (G, H) Ihh & PTHrP factor production of RC cells. Mean ± SE, groups
not sharing a letter are statistically different (α = 0.05), NT no treatment, NC negative control microRNA.
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three different concentrations, with and without the corresponding mimic along with a NT group
and a mimic only group. Alkaline phosphatase activity and total DNA production were assayed.
Response of GC Chondrocytes
MicroRNA 22-3p decreased DNA production and this effect was reversed by transfection
alongside the inhibitor with inhibitor alone having a slight reduction in DNA production compared
to NT (Fig. 2.6 A). Alkaline phosphatase activity was not significantly different for all but the mimic
plus inhibitor (30 or 50 nM) groups where slight decreases were observed (Fig. 2.6 B).
MicroRNA 122-5p inhibitor alone had no effect on total DNA production, 122-5p mimic
alone increased DNA production and mimic + inhibitor was able to reduce DNA production but
not back to NT levels (Fig. 2.6 C). Alkaline phosphatase activity underwent no change with
inhibitor alone but was significantly reduced when transfected with 122-5p mimic on its own. The
addition of 122-5p inhibitor to the mimic increased the alkaline phosphatase activity but was
unable to return it to the NT level (Fig. 2.6 D).
Response of RC Chondrocytes
MicroRNA 22-3p decreased total DNA production when compared to all other groups. The
addition of inhibitor to the mimic was able to bring DNA production nearly back to the NT group.
Transfection with inhibitor alone resulted in a slightly greater decrease of total DNA production
compared to mimic combined with inhibitor (Fig. 2.6 E). Alkaline phosphatase activity was largely
unaffected by the 22-3p inhibitor alone with the highest concentration (50 nM) resulting in a slight
decrease. Mimic alone resulted in a significant decrease that was largely reversed by addition of
inhibitor (Fig. 2.6 F).
MicroRNA 122-5p inhibitor alone had no significant effect on total DNA production, mimic
alone produced a significant increase in DNA production that was partially reversed by addition
of inhibitor (Fig. 2.6 G). Similarly, the addition of inhibitor on its own resulted in no significant
difference in alkaline phosphatase activity, whereas the 122-5p mimic on its own significantly
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reduced alkaline phosphatase activity, which was partially reversed by addition of inhibitor (Fig.
2.6 H).

Figure 2.6 Selective microRNA inhibitors effect on GC and RC cells at 48 hrs. (A–D) Response of GC
cells, (A, B) total DNA & alkaline phosphatase activity following transfection with 22-3p, (C, D) following
transfection with 122-5p. (E–F) Response of RC cells, (E, F) total DNA and alkaline phosphatase activity
following transfection with 22-3p, (G, H) following transfection with 122-5p. Mean ± SE, groups not sharing
a letter are statistically different (α = 0.05), NT: no treatment.

Angiogenesis
MicroRNA 122-5p had a clear visual effect on HUVECs when compared to scrambled
vector transfection (Fig. 2.7 A) and also resulted in a decrease in total DNA production when
compared to NC (Fig. 2.7 B). MicroRNA 22-3p, 122-5p, 223-3p, and 451-5p all resulted in a
decrease in the connection length at 20 hours with only microRNA 122-5p and 451-5p driving a
reduction in connection number (Fig. 2.7 C).
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Figure 2.7 Angiogenesis of HUVEC cells following transfection. (A) Representative images of NC and
122 transfection at 20 hours. (B) Total DNA production by HUVEC cells at 48 hours. (C) Connection
length and connection number counted every 4 hours over a 20 hour time period. Mean ± SE, groups not
sharing a letter are statistically different (α = 0.05), * and x are statistically different from NC (α = 0.05),
NC: negative control microRNA

Discussion
This study using rat costochondral cartilage cell cultures as a model system, demonstrates
the potential of growth plate chondrocyte microRNA, packaged in MVs and exported into the
ECM, to exert a regulatory influence back on the chondrocytes in a paracrine and potentially
autocrine fashion. These selectively packaged microRNA produce clear and maturation zone
dependent effects on growth plate chondrocytes.[2,55] Establishing regulatory capability for MV
microRNAs lays out additional roles for MVs, providing protection against degradation for
microRNA and directly modulating chondrocyte gene expression.[35,64] MicroRNA have robust
potential as a regulatory molecule as a result of each microRNA’s ability to impact the production
of multiple proteins within a cell.
Our study examined the effects that MV microRNAs can exert on growth plate
chondrocytes. Previous work examined the importance of microRNA for a functioning growth plate
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and the role that microRNAs have in regulating factor production.[144,145] This study found two
microRNA that exhibited significant maturation dependent regulatory effects on chondrocytes.
MicroRNA 22-3p demonstrated an ability to modulate ECM and factor production by both RC and
GC chondrocytes. MicroRNA 122-5p demonstrated a maintenance type of effect increasing
production of components associated with healthy cartilage while delaying terminal differentiation
and increasing proliferation.
MicroRNA 122-5p transfection resulted in consistent responses from both RC and GC
cells that are characteristic of proliferating chondrocytes. Cell proliferation increased, alkaline
phosphatase activity decreased and sGAG production increased (with GC cells approaching
levels found in RC cells). To further study the maintenance aspect of microRNA 122-5p we used
HUVEC cells to examine the potential angiogenic effect of microRNA 122-5p in the growth plate
(an avascular tissue). When transfected into HUVEC cells, microRNA 122-5p drove a reduction
in both connection number and length between the cells indicating a potential inhibitory effect on
blood vessel formation useful for avascular tissue maintenance.
A stark response demonstrated by both RC and GC chondrocytes to microRNA 122-5p
transfection was an increase in proliferation that may be connected to the reduction of both Ihh
and PTHrP production that was also observed. Proliferating cells of the growth plate are located
within the PTHrP and Ihh feedback loop sandwiched by resting cells producing PTHrP on one
end and cells differentiating to a hypertrophic phenotype and producing Ihh on the other. Between
these two regions chondrocytes are proliferating with expression of Ihh and PTHrP largely
absent.136 Whether the reduction in PTHrP and Ihh is driving the increase in proliferation or if other
effectors are involved is unknown. What was made very clear is that microRNA 122-5p has
numerous impactful effects on growth plate chondrocytes (increasing proliferation, stopping
vascularization and maintaining production of ‘healthy’ ECM).
The response of both RC and GC cells to microRNA 22-3p was unexpected. Transfection
with microRNA 22-3p was able to impact the ECM composition of both chondrocyte populations,
as well as proliferation and differentiation markers of RC cells. Its strongest impact was on factors
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produced by cells from both growth plate zones. Although microRNA 22-3p was active in both RC
and GC chondrocytes, it did not appear to drive either population of cells toward a more
proliferative or hypertrophic phenotype. Instead, it increased the production of proteins that are
characteristic of both regions. MicroRNA 22-3p’s relatively abundant presence in RC and GC cells
and their corresponding MVs, the observed response of chondrocytes to microRNA 22-3p
transfection not being characteristic of either zone indicate that it is potentially functioning as part
of a larger microRNA regulatory network within growth plate chondrocytes.[146]
As a result of microRNA 22-3p and 122-5p exhibiting the majority of effects we decided to
assess the specificity of these mimics by transfecting them along with their specific inhibitor. Both
mimics and inhibitor are transfected as double stranded RNA molecules that require cellular
processing in order to be activated. We observed partial or complete reversal of the effects of the
mimic when transfected alongside specific inhibitors. It is likely that a portion of the mimics are
loaded into the RNA induced silencing complex and able to regulate available mRNA before being
sequestered by the co-transfected inhibitors even when the inhibitor is administered at three times
the concentration of the mimic.
In addition to examining the specificity of the mimics, we wanted to verify the presence of
these microRNA in tissue samples to ensure they are not an artifact of cell culture. Our first
approach was using a NanoString microRNA panel to examine RNA isolated from GC and RC
tissue samples. At first glance, the absence of microRNA 122-5p and 223-3p in any of the tissue
samples and microRNA 451-5p in the RC tissue samples are concerning. However, in the
RNAseq data these microRNA range from 0 to 4.9 x 10-4% in the cell samples and 4.3 x 10-3 to
1.1% in the MV samples. The quantity of MV RNA that is isolated from cell culture preparations
is very low compared to the corresponding cell pellet (average of 300 times less according to
bioanalyzer analysis, data not shown). These three microRNA (122-5p, 223-3p & 451-5p) were
found primarily if not exclusively in the MV isolation and so are likely to be present in extremely
low numbers in actual tissue. Results from the NanoString are not conclusive that the microRNA
are not present in native tissue given the low read numbers in the RNAseq data from tissue
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culture. Colleagues in our lab have found microRNA 122-5p and 451-5p in articular cartilage using
qPCR from ex vivo samples.[147] Additionally, a recent publication comparing four different
microRNA quantification methods (small RNAseq, FirePlex, EdgeSeq and nCounter) found the
nCounter system to be the least sensitive of the four with fewer microRNAs determined to be
above background levels.[148] MicroRNA 22-3p was found by the NanoString panel in both RC
and GC tissue samples (average of 11.19% and 5.15% respectively). These values are similar to
the results from the small RNAseq data (cells: 2.2% RC and GC, MV: 20% RC and 17% GC).
These data do confirm the presence of both microRNA 22-3p and 451-5p in ex-vivo GC tissue
samples.
In order to further validate the presence of the microRNA in tissue we performed RT-qPCR
on RNA isolated from RC and GC tissue. The standard curve generated produced an upward
trend in CT values as the dilution increased for snRNA U6 (positive control) and microRNA 223p. There is no clearly discernable trend for microRNAs 122-5p and 451-5p however the ability
to amplify a detectable product was lost as dilutions increased. In a similar fashion all snRNA U6
and microRNA 22-3p samples fell below 35 CT (a commonly used cut off point for mRNA RTqPCR) along with all but one of the GC microRNA 122-5p and 451-5p groups. Both the increase
in CT values from microRNA 22-3p to microRNAs 122-5p and 451-5p and the standard curve
becoming undetectable for microRNAs 122-5p and 451-5p follows the trend that was observed in
the small RNAseq data with microRNA 22-3p being more abundant than either microRNAs 1225p or 451-5p. These RT-qPCR results provide compelling evidence of their presence at a low
level in tissue (Supplemental Fig. 2.1).
Investigating the in vivo chondrocyte response to microRNA 22-3p and 122-5p is an
intriguing next step. MicroRNA 122-5p transfection was able to generate a response from both
RC and GC cells that was analogous to proliferating chondrocytes while the strong factor
response to microRNA 22-3p makes both microRNAs interesting candidates for future animal
studies. Delivery of targeted cocktails of microRNA packaged into vesicles look to be potential
methods for treating cartilage disorders. A more detailed understanding of MV packaging and
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release would be beneficial in designing treatment delivery mechanisms that closely mimic
existing biological systems.
This study demonstrates that microRNA, first discovered in cell culture isolations, are likely
involved in the complex regulation of growth plate chondrocytes as they proliferate and mature.
These microRNA that are exported into the ECM within MVs are able to produce phenotypic
effects on growth plate chondrocytes that fall within understood zonal behaviors for these cells.
Gaining a better understanding of the regulation that microRNA production and export falls under
as well as a more precise view into the regulatory effects that individual microRNA are able to
elicit will be fundamental in selecting microRNA for potential treatment avenues.
Experimental Procedures
Chondrocyte Cultures
Costochondral cartilage was removed from 100 to 125 g male Sprague Dawley rats,
isolated by enzymatic digestion and cultured as previously described by Boyan et al.[8,91] All
animal procedures followed a protocol approved by the Institutional Animal Care and Use
Committee at Virginia Commonwealth University. Animals were killed by CO2 asphyxiation
followed by cervical dislocation. Rib cages were removed by sharp dissection and placed in
Dulbecco’s modified Eagle’s medium (DMEM; Life Technologies, Carlsbad, CA) containing 1 g/L
glucose with 150 U penicillin/mL and 150 μg streptomycin/mL (Lonza, Basel, Switzerland). Tissue
was removed from around the ribs and RC and GC cartilage sections were dissected out. A small
region of GC tissue was between the bone and RC tissue and the three different regions were
clearly visible under a dissection scope. One or two transition slices between the RC and GC
regions were discarded and the dissected tissue incubated overnight in DMEM. RC and GC slices
were incubated in 0.25% trypsin-EDTA (Gibco, Gaithersburg, MD) for 1 hour, washed and
incubated in 0.2% collagenase type II (Worthington Biochemical, Lakewood, NJ) for 3 hours on a
shaker. Cells were filtered through a 40 µm nylon mesh strainer, collected by centrifugation (751
g for 10 minutes) and re-suspended in DMEM FM (1 g/L glucose DMEM with 10% FBS, 50 U/mL
penicillin, 50 μg/mL streptomycin and 50 µg/mL ascorbic acid). Cells were plated at a density of
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20,000 GC cells/cm2 or 10,000 RC cells/cm2 and incubated at 37˚C and 5% CO2. The culture
media were changed 24 hours after plating and then every 48 hours thereafter. Confluent cells
were passaged using 0.25% trypsin and plated as above. Fourth passage cells were used for all
experiments.
Bioinformatic Analysis
Small RNA-seq data from chondrocytes and MVs that were isolated in a previous study
(Lin et al. 2016) were used for this study.[2] Reads were aligned against the rat genome and
analyzed using the miARma-Seq tool.[149] In brief the read quality was assessed using FASTQC;
reads were aligned to the NCBI Rattus norvegicus annotation release 105 (Rnor_6.0) using
Bowtie2. Resulting bam files were processed by miARma-Seq to quantify microRNAs and
differential expression calculated using edgeR.[150] Normalized read counts from edgeR were
used to determine the percent of each microRNA in the sample 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑛𝑛𝑡𝑡 𝑋𝑋 𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚 =
�

𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚
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for each of the 111 DE microRNA.

Nanostring
We used NanoString’s nCounter system to quantify the presence of microRNA in
costochondral tissue. Tissue slices were harvested, cleaned and directly transferred to Qiazol
lysis reagent (Qiagen, Hilden, Germany) for homogenization with no intermediate. In brief, the RC
and GC zones were carefully cut into thin slices taking extra care to remove surrounding tissue
from the ribs and discarding one or two slices separating the zones. The tissue was not exposed
to media or FBS. Cartilage slices (avg ~15 mg per sample) were transferred to BeadBug
homgenizer tubes (Benchmark Scientific, Sayreville, NJ) with 6.0mm zirconium bead (previously
treated to degrade any contaminating RNA: 2 hours under UV light and 2 hours in 75˚C). 700 μL
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Qiazol was added to the tube and slices were homogenized on a BeadBug (cycle settings: speed
= 400, time = 40 sec) with GC slices requiring 19 cycles for homogenization and 8 cycles for RC
samples. RNA was extracted using Qiagen’s miRNeasy micro kit and resuspended in nuclease
free water. Samples were submitted for analysis at the Biobehavioral Research Lab at VCU using
Nanostring’s Rat v1.5 miRNA panel.
Ex-Vivo RT-qPCR
Tissue was removed in identical manner to ‘chondrocyte cultures’ above. Following trypsin
digestion, tissue slices were washed with Hank’s Balanced Salt Solution (HBSS) and deposited
into a BeadBug homogenizer tube (same tube and treatment as ‘Nanostring’). 700 μL of Qiazol
was added to the tube and allowed to sit at room temperature for 5 minutes. GC and RC tubes
were then run on the BeadBug homogenizer (cycle settings: speed = 400, time = 60 sec) for four
cycles. RNA was purified using Qiagen’s miRNeasy micro kit and resuspended in nuclease free
water. RT-PCR was performed on four GC and RC samples normalized to 1,250 ng of RNA per
well using Qiagen’s HiSpec Buffer and incubating in thermocylcer at 37˚C for 60 min followed by
95˚C for 5 min. qPCR was run on the resulting cDNA diluted to a final working concentration of
3.125 ng/μL using Qiagen’s miScript II RT kit and primers for snRNA U6, microRNA 22-3p
(Qiagen), 122-5p and 451-5p (Eurofins Scientific, Luxembourg). An eight-point standard curve
was generated by mixing 4 μL from each of the eight samples together and performing a 1:3 serial
dilution starting at 5 ng/μL and run in duplicate. 10 μL reactions were run in a 96 well plate using
a QuantStudio 3 RT-PCR system (ThermoFisher): activation: 95˚C for 15 min, 60 cycles of
(denaturation: 94˚C for 15 sec, annealing: 55˚C for 30 sec, extension: 70˚C for 30 sec) followed
by melt curve. Data was collected on the extension and melt curve steps.
MicroRNA Transfection
Once fourth passage chondrocytes were 60 – 70% confluent they were transfected with
microRNA mimics (mirVana; Invitrogen, Carlsbad, CA) at final concentration of 14.5 nM using
Lipofectamine RNAiMAX transfection reagent (Invitrogen) at a final dilution of 1:500. Four
microRNA mimics were used for these experiments: (microRNA 22-3p, 122-5p, 223-3p and 451-
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5p). Transfection was carried out in DMEM 1 g/L glucose with 10% FBS and incubated at 37 ˚C
and 5% CO2 for 24 hours. At transfection completion the media were changed to DMEM FM until
harvest. Harvest was carried out according to the requirements of each specific assay with
reported hours being hours post transfection completion. Two control groups were included in the
experiments: a NT group that received neither lipofectamine nor microRNA mimics and a NC
group that included lipofectamine along with a mimic designed not to interact with known mRNA.
Specific microRNA inhibitors (22-3p and 122-5p miRCURY LNA miRNA Inhibitors,
Qiagen) were transfected following the same procedure as for the microRNA mimics. Final
concentration of microRNA inhibitors was 10, 30 or 50 nM. When transfected along with
microRNA mimics the inhibitors were prepared and administered together with the mimics in one
treatment solution. Lipofectamine concentration and media formulations unchanged. MicroRNA
inhibitors for 223-3p and 451-5p were not investigated.
Cell Response
DNA Content
Double stranded DNA was quantified after sonicating the cell monolayer (40 amps, 10 sec
per well) and assaying bound fluorescent dye (QuantiFluor® dsDNA system; Promega, Madison,
WI) using a plate reader (Synergy H1 Hybrid Reader; BioTek, Winooski VT) with excitation of 485
nm and emission of 538 nm.
Proliferation Rate
Four hours before indicated timepoint cells were pulsed with EdU at 10 μM concentration
and incubated at 37 ˚C for four hours. Cells were then fixed, labeled and read (excitation 568 nm
emission 585 nm) according to manufacturer’s protocol (Click-iT® EdU Microplate Assay;
Invitrogen) to quantify all EdU that was incorporated by the actively proliferating cells during the
four hour pulse.
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Metabolic Activity
100 μL of MTT solution (5 mg/mL in PBS) was added to the 500 μL of serum-free media
per well and incubated at 37 ˚C for four hours. Media was aspirated and replaced with 500 μL of
DMSO per well and placed on a shaker for 5 minutes. 200 μL of the DMSO per well was
transferred to a 96 well plate and absorbance read at 570 nm.
Production of Proteins
Proteins were quantified by ELISA normalized to DNA content. Assays were carried out
following accompanying protocols for: BMP-2 (PeproTech, Rocky Hill, NJ), type II collagen, type
X collagen, Ihh, p53 and PTHrP (LS Bio, Seattle, WA), OPG, TGF-β1 and VEGF (R&D Systems,
Minneapolis, MN). Media and cell monolayer were isolated at 48 hours.
In cell western analysis was used to quantify specific protein levels with results normalized
to DNA content. At 48 hours cells were fixed using 3.7 % formaldehyde, with 0.1 % Triton X-100,
blocked for 1.5 hours (Odyssey Blocking Buffer) and incubated overnight at 4 ˚C with primary
antibody specific for Bax or Bcl at 1:100 and 1:20 dilution respectively. Wells were washed and
incubated for 1 hour at room temperature with DRAQ5 (1:10,000 dilution) and corresponding
secondary antibody (1:1,000 dilution). Wells were washed and imaged on the Li-Cor Odyssey
CLx (LI-COR, Lincoln, NE).
TUNEL
Cells were fixed with 3.7 % buffered formaldehyde solution, permeabilized with proteinase
K and labeled with TdT labeling buffer. Absorbance was measured at 450 nm on a plate reader.
Alkaline Phosphatase Activity
At 48 hours media were aspirated and cell monolayer washed twice with 1 X PBS.
Monolayer was removed with 0.05% Triton X 100 and lysed by three cycles of freeze thawing.
Alkaline phosphatase activity was quantified using a colorimetric assay that determines the
amount of enzyme needed to hydrolyze 1 µmole of p-nitrophenyl phosphate to 1 µmole of p-
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nitrophenol at 37 ˚C. Absorbance was read in plate reader at 405nm. Activity was normalized to
protein content as determined by Pierce BCA assay (ThermoFisher, Waltham, MA).
Sulfated Glycosaminoglycan Production
At 48 hours media were aspirated and cell monolayer washed twice with 1 X PBS. Cell
monolayer was removed from wells with papain digest solution (3.8 U/mL papain in 55 mM sodium
citrate, 10 mM cysteine) and digested overnight at 60 ˚C. sGAG content was assessed using 1,9dimethylmethylene blue dye with pH of 1.5 and absorbance measured at 525 nm on a plate
reader.
Regulation of Vasculogenesis
HUVECs were grown on Geltrex and cultured using endothelial cell growth media from
the Angiogenesis Starter Kit (ThermoFisher). The four select microRNA were transfected into
HUVECs, as detailed above, and the connection length (measured in pixels) and the connection
count taken every four hours over a 20 hour period.
Statistical Analysis
DNA content, proliferation rate, MTT, ELISA, in cell western, TUNEL, alkaline
phosphatase activity and sGAG are presented as mean ± standard error for six independent
cultures per variable. Differences between groups were examined by ANOVA with post-hoc Tukey
HSD. A p-value less than 0.05 was considered significant. Experimental observations validated
with at least one repeat experiment. Connection length and number examined by ANOVA with
post-hoc Tukey HSD. Significance discussed is between treatment and NC group based on a pvalue less than 0.05. Statistical analysis and presentation for all examinations were carried out
using R 3.6.0.[151] Following R packages were used: egg, grid, gridExtra, ggplot2, ggsignif,
magrittr, multcompview, outliers, plyr and sfsmisc.[151–160]
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Supplementary materials

Supplemental Figure 2.1 RT-qPCR melt curve and standards. (A) Melt curves for RC and GC for all four
primers. (B) Cycle threshold values for standards diluted from 5 to 0.002 ng / μL. Mean ± SE.
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1α,25-Dihydroxyvitamin D3 Regulates Packaging of
microRNAs within Extracellular Matrix Vesicles and
Their Release in the Matrix

Under Review

Abstract
Chondrocytes in the growth plate are regulated by numerous factors and hormones as
they mature during endochondral bone formation. Chondrocytes in the growth zone (GC) of the
growth plate produce and export matrix vesicles (MVs) into the extracellular matrix under the
regulation of 1α,25-dihydroxyvitamin D3 [1α,25(OH)2D3]. In addition, 1α,25(OH)2D3 secreted by
the cells acts directly on the MV membrane, releasing its contents into the matrix. This study
examined the regulatory role that 1α,25(OH)2D3 has over the production and packaging of
microRNA into MVs by GC chondrocytes along with the ability to release microRNA from MVs
once they are in the extracellular matrix in order to regulate cartilage maturation. We treated GC
chondrocytes with 1α,25(OH)2D3 for 24 hours and then sequenced the microRNA in the cells and
MVs. We also treated MVs with 1α,25(OH)2D3 and determined if the microRNA was released into
solution. Finally, to assess whether MVs can act directly with cartilage cells and if this is regulated
by 1α,25(OH)2D3, we stained isolated MVs with a membrane dye and used them to treat GC
chondrocytes. 1α,25(OH)2D3 regulated the production and packaging of microRNA into matrix
vesicles but did not affect the cell population of microRNA. MicroRNA were not released when
MVs were treated with 1α,25(OH)2D3, indicating a heterogeneous MV population or retention
within the MV via a protective factor. Stained MVs were endocytosed by GC cells in vitro and this
was increased with 1α,25(OH)2D3 treatment. This study adds a new regulatory role for
1α,25(OH)2D3 with respect to packaging and transport of microRNA in MVs and their interaction
with GC chondrocytes.
Introduction
Chondrocytes are the drivers of elongation within mammalian growth plates and are
responsible for endochondral ossification.[161] During this process chondrocytes are arranged in
well-organized columns as the cells move from the reserve zone (resting zone cartilage, RC)
where the cells maintain a hyaline-like extracellular matrix (ECM) consisting of large proteoglycan
aggregate and type II collagen. Cells in the lower reserve zone are actively proliferating,
transitioning into the growth zone (GC), which includes the prehypertrophic zone and the upper
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hypertrophic zone, where the cells increase in size and remodel their ECM, in preparation for
mineralization.[12]

Key

players

in

the

mineralization

process

are

matrix

vesicles

(MVs).[29,34,131] They are small (50 to 150 nm in diameter) lipid bound vesicles produced by
the chondrocytes and secreted by lateral budding off into the ECM.[19] MVs produced by GC
cells contain enzymes needed for ECM mineralization, including matrix processing enzymes such
as the matrix metalloproteinases (MMPs) and enzymes involved in calcium phosphate deposition
such as alkaline phosphatase, along with factors and microRNA for chondrocyte
regulation.[9,36,37]
Vitamin D metabolites are involved in both rapid acting and genomic regulation of this
entire process and the specific metabolite involved is zone dependent. RC cells respond primarily
to 24R,25-dihydroxyvitamin D3 [24R,25(OH)2D3] with an increase in alkaline phosphatase activity
and the stimulation of cell proliferation while GC cells primarily respond to 1α,25-dihydroxyvitamin
D3 [1α,25(OH)2D3] by decreasing cell proliferation and increasing alkaline phosphatase
activity.[6,121,133] This zonal specificity holds true for MVs produced by these cells.
24R,25(OH)2D3 regulates the production of RC MVs, which exhibit increased alkaline
phosphatase activity and a reduction in phospholipase A2 (PLA2) activity. In contrast,
1α,25(OH)2D3 regulates the production of GC MVs, with an increase in both alkaline phosphatase
and PLA2 activity.[3,57]
Vitamin D3 is taken up in the body through one’s diet or by being synthesized from 7dehydrocholesterol in the skin in the presence of ultraviolet irradiation.[162] Vitamin D3 is then
transported to the liver bound to the vitamin D binding protein and hydroxylated at carbon 25 to
become 25-hydroxyvitamin D3 [25(OH)D3] the primary circulating form of vitamin D.[162]
Cartilage is not vascularized, however, making local production of many regulatory factors
important for controlling chondrocyte proliferation, differentiation, and maturation. RC and GC
cells, in addition to the kidney, are able to use the circulating 25(OH)D3 to produce metabolically
active 24R,25(OH)2D3 and 1α,25(OH)2D3.[162,163] These metabolites are secreted by the
chondrocytes into the ECM under cell-specific regulation, where they interact directly with the MV

Asmussen | MicroRNA in the Mammalian Growth Plate: Matrix Vesicles and 1α,25-Dihydroxyvitamin D3

74

membrane. Whereas 24R,25(OH)2D3 stabilizes the MV membrane, 1α,25(OH)2D3 destabilizes it
through the activation of PLA2, releasing the MV contents into the ECM.[7]
In addition to its direct action on MVs in the ECM, 1α,25(OH)2D3 is able to regulate GC
cells through both genomic and rapid acting pathways. The genomic effect of 1α,25(OH)2D3 is
realized through binding of 1α,25(OH)2D3 with the nuclear vitamin D receptor (nVDR), which forms
a heterodimer within the nucleus and is able to bind to vitamin D response elements (VDRE)
located in the promoter regions of target genes.[164] nVDR has over 1,000 target genes in human
tissues and in chondrocytes has been shown to upregulate receptor activator of NF-κΒ ligand
(RANKL) and vascular endothelial growth factor (VEGF) production.[165,166] Rapid acting
effects of 1α,25(OH)2D3 in GC chondrocytes take place through the membrane associated vitamin
D receptor protein disulfide isomerase, family A, type 3 (PDIA3) (also known as 1,25 membraneassociated rapid response steroid-binding proteins [1,25-MARRS]), as well as the classical VDR.
Membrane-associated VDRs are able to regulate chondrocytes through various signal
transduction systems (e.g. PLA2, phosphatidyl inositol 3-kinase [PI3K], protein kinase A and C
[PKA and PKC] pathways that increase cytosolic calcium levels and activate transcription factors
nuclear factor kappa Β [NF-κΒ] and extracellular-signal regulated kinase [ERK] 1/2) that elicit both
a rapid response and activation of transcription factors.[121,164,167–169] In addition to the
documented effects of 1α,25(OH)2D3 on chondrocytes and the pathways involved, 1α,25(OH)2D3
has been demonstrated to regulate microRNA production in other cell types including cancer cells
and peripheral blood mononuclear cells.[170]
As noted above, 1α,25(OH)2D3 is involved in regulating the activity of MVs produced by
growth plate chondrocytes. MVs lack a nucleus and the requisite machinery for genomic
transcription and translation leaving rapid acting pathways as the method of action for MVs.
During the production of MVs the PDIA3 receptor is associated with the lipid membrane.[96] In
the ECM, 1α,25(OH)2D3 binds to PDIA3 on GC MVs and activates PLA2, hydrolyzes membrane
phospholipids to produce lysophospholipids, destabilizing the MV membrane.[43] One
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consequence is the release, among other things, of stromelysin 1 (MMP-3), which activates latent
TGF-β1 that has been secreted by chondrocytes into the ECM.[64,65,171]
We have recently demonstrated that growth plate chondrocytes produce MVs with a
population of microRNA that is distinct from the parent cell, the MV RNA is safe from RNase
activity, and that some of these microRNA are able to regulate the activity of both RC and GC
cells.[2,9,55] 1α,25(OH)2D3 regulates numerous aspects of GC MV production including enzyme
packaging and has been found to regulate microRNA production in other cell types. This leads to
a clear question of whether 1α,25(OH)2D3 is regulating the production and/or packaging of
microRNA into GC MVs as part of its regulatory role in the growth plate. In addition to the export
of microRNA, we examined the ability of 1α,25(OH)2D3 to release microRNA from GC MVs and
the impact that 1α,25(OH)2D3 has on the binding/endocytosis of GC MVs by GC cells.
Methods
Chondrocyte Cultures
Costochondral cartilage was removed from 100 to 125 g male Sprague Dawley rats. RC
and GC chondrocytes were isolated by enzymatic digestion and cultured as previously described
by Boyan et al.[8,91] All animal procedures conducted during the course of this work followed a
protocol approved by the Institutional Animal Care and Use Committee (IACUC) at Virginia
Commonwealth University. Experiments were carried out in accordance with all relevant
guidelines and regulations. In brief, animals were killed by CO2 asphyxiation followed by cervical
dislocation. Rib cages were removed by sharp dissection and placed in Dulbecco’s modified
Eagle’s medium (DMEM, Life Technologies, Carlsbad, CA) 1 g/L glucose with 150 U/mL penicillin
and 150 μg/mL streptomycin. All tissue was removed from around the ribs and the RC and GC
cartilage sections were dissected out discarding one or two transition slices. The cartilage slices
were incubated in 0.25% trypsin-EDTA (Gibco, Gaithersburg, MD) for 1 hour, washed and
incubated in 0.2% collagenase type II (Worthington Biochemical, Lakewood, NJ) for 3 hours on a
shaker. Cells were filtered through a 40 µm nylon mesh strainer, collected by centrifugation (500
g for 10 minutes) and re-suspended in DMEM FM (1 g/L glucose DMEM with 10% FBS, 50 U/mL
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penicillin, 50 µg/mL streptomycin, and 50 µg/mL ascorbic acid). Cells were plated at a density of
20,000 GC cells/cm2. Cells were incubated at 37˚C and 5% CO2 and the culture media were
changed 24 hours after plating and then every 48 hours thereafter. Confluent cells were passaged
using 0.25% trypsin and plated as above. Fourth passage cells were used for all experiments.
1α,25(OH)2D3 Treatment
Fourth passage GC cells were grown out to 100% confluency. 24 hours later the media
were aspirated and replaced with fresh media containing 10-8 M 1α,25(OH)2D3 for 24 hours at
which time the matrix vesicles were isolated, as described below.
Materials
Unless otherwise indicated: 0.9% NaCl was 0.2 µm filtered, ultracentrifugation was
performed in 32.5 mL straight wall tubes (Beranek Laborgeräte, Nuβloch, Germany) using a 50.2
Ti fixed-angle rotor (Beckman Coulter, Indianapolis, IN), and exosome depleted FBS was derived
from heat inactivated FBS (Life Technologies) that was centrifuged to remove exosomes (30 mL
of FBS was spun [238,668 g for 4 hours at 4 ˚C] after which the top 10 mL of supernatant was
carefully pipetted off and 0.2 µm filtered for use in MV isolation and the remaining 20 mL was
discarded).
MV Isolation
Media were aspirated from the culture flask and discarded. The cell layer was washed
with 1X DPBS and the MVs were separated from the ECM by digesting the cell layer with 0.25%
trypsin and following that with differential centrifugation as has been described previously.90 In
brief: fourth passage GC cells in T-175 flasks were incubated in 10 mL 0.25% trypsin for a total
of 10 min at 37˚C. At minute 4, the bottom of each flask was gently scrapped to ensure
detachment of the cell monolayer and aid in initial breakdown of the ECM. After being scrapped
the flasks were returned to 37˚C for the remainder of the 10 min. 10mL 1X DPBS with 10%
exosome depleted FBS was used to quench the trypsin. The MVs were isolated from the digested
ECM/cell suspension by differential ultracentrifugation. The suspension was spun (500g for 10
min at 4˚C) in a benchtop centrifuge to pellet the cells leaving MVs in the supernatant. The MV
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supernatant was poured off and stored in -80 ˚C and the cell pellet resuspended in 10 mL 0.9%
NaCl. Two 1 mL aliquots were made from the resuspended cell pellet and spun (500g at 4˚C for
10 min) in a benchtop centrifuge. The supernatant was discarded and one pellet resuspended in
700 μL of Qiazol lysis reagent (Qiagen, Hilden, Germany) for RNA extraction as described below,
and the other in 200 μL of NP-40 lysis buffer (Boston BioProducts, Ashland, MA) with 1% protease
inhibitor cocktail (Sigma, St. Louis, Missouri) for alkaline phosphatase activity. The remaining 8
mL of cell pellet resuspension was spun down (500g at 4˚C for 10 min) in a benchtop centrifuge
and resuspended in 5 mL 0.25 M sucrose solution (0.25 M sucrose, 1 mM EDTA tetrasodium salt,
100 mM Tris) for plasma membrane isolation. All suspensions were stored at -80˚C.
To obtain the MVs, the MV supernatant was thawed on ice and processed in an
ultracentrifuge. Any cell debris was spun down (24,000g for 20 min at 4˚C) and the resulting
supernatant was transferred to new tubes and spun (100,000g for 70 min at 4˚C) to pellet the
MVs. The supernatant was discarded and the vesicle pellet was washed with 20 mL 0.9% NaCl
at 4˚C and centrifuged again (100,000g for 70min at 4˚C). This final supernatant was discarded
and the MV pellet was resuspended in fresh 0.9% NaCl (100 μL for RNA, 200 μL for MV microRNA
release and MV endocytosis, and 500 μL for alkaline phosphatase activity).
Validation of MV Isolation
Plasma membrane suspension was thawed on ice, poured into a glass homogenizer, 1
mL 0.25 M sucrose was added to sample tube, vortexed and added to homogenizer, tube was
then rinsed with an additional 2 mL 0.25 M sucrose that was poured into homogenizer. The pestle
was inserted into homogenizer, rotated 360˚ and lifted up. This was repeated a total of five times.
The sample was poured out of homogenizer into ultracentrifuge tube, pestle and homogenizer
were each rinsed with 2 mL 0.25 M sucrose solution that was poured into same ultracentrifuge
tube. The tube was spun (1,480g at 4˚C for 20 min) and supernatant was discarded. The pellet
was resuspended with 2 M sucrose solution and spun (20,000g at 4˚C for 20 min) and supernatant
was poured off into a new ultracentrifuge tube. The tube was filled with ice cold ultrapure water
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and spun (40,000g at 4˚C for 30 min). The supernatant was carefully poured off and the plasma
membrane (PM) pellet resuspended in 1 mL of 0.9% NaCl.
MV, plasma membrane, and cell pellet (in NP-40) isolates had alkaline phosphatase
activity quantified with a colorimetric assay that specifies the amount of phosphatase used at 37˚C
to hydrolyze 1 µmole of p-nitrophenyl phosphate to 1 µmole of p-nitrophenol. Sample absorbance
was quantified using a plate reader at 405 nm. Enzyme activity was normalized to sample protein
content as determined by the Pierce BCA assay for cell pellet and plasma membrane and the
micro BCA assay for MV samples (ThermoFisher, Waltham, MA).
RNA Analysis
Immediately after isolation, the MV pellets were resuspended in the 100 µL volume
remaining in the centrifuge tube after decanting the supernatant and mixed with 700 μL Qiazol
lysis reagent. Exosome depleted FBS was processed as above and resuspended in 100 μL 0.9%
NaCl for RNA extraction. All samples were stored at -80˚C. After thawing, samples in Qiazol were
processed using Qiagen’s miRNeasy mini kit following the standard protocol for purification of
total RNA from animal cells. In brief, chloroform was added, aqueous phase was removed and
combined with ethanol, RNA was bound to a spin filter and washed with RWT and RPE buffers.
MV and exosome depleted FBS samples were eluted in 30 μL of nuclease free water per sample
and cell pellet samples in 50 μL.
RNA isolations were quantified with a RNA 6000 pico chip on a BioAnalyzer (Agilent,
Santa Clara, CA). Samples were then pooled to maximize RNA distribution between the MV
groups and submitted for smallRNAseq (ArrayStar, Rockville, MD) that included quality control,
library construction, and sequencing on an Illumina instrument (Illumina, San Diego, CA).
MicroRNA Bioinformatic Analysis
Bioinformatic Analysis of smallRNAseq
Raw read files were processed with the miARma-Seq tool that evaluated read quality with
FASTQC, aligned the reads using Bowtie2 against the Rattus norvegicus (Rnor_6.0) genome,
and generated a count of the microRNA from the bam files. Bioinformatic analysis was carried
Asmussen | MicroRNA in the Mammalian Growth Plate: Matrix Vesicles and 1α,25-Dihydroxyvitamin D3

79

out using R version 4.0.3, normalization and differential expression were calculated with DESeq2,
Venn diagrams built using VennDiagram, heatmaps with pheatmap and the static parallel
coordinate plots with bigPint.[150,151,172]
miEAA Analysis
MicroRNA from four different comparisons (cell vehicle – cell 1α,25(OH)2D3, MV vehicle –
MV 1α,25(OH)2D3, cell vehicle – MV vehicle, and cell 1α,25(OH)2D3 – MV 1α,25(OH)2D3) with
absolute log 2 fold change > 1 and a p-value < 0.05 were uploaded to the miRNA enrichment
analysis and annotation 2.0 tool (miEAA 2.0) and run through the over-representation analysis
(ORA) pipeline.[83] Resulting annotations were searched for musculoskeletal associated terms
(Table 1). Results from the full ORA as well as the musculoskeletal focus was loaded into
Cytoscape 3.8.2 to visualize the microRNA interactions.
MV microRNA Release
We previously showed that MV metalloproteinases are released when MVs are treated
with either detergent or 1α,25(OH)2D3 and small RNAs are released when MVs are treated with
detergent, making them susceptible to degradation by RNAse.[55,64] In order to determine if
microRNAs are released following loss of MV membrane integrity due to 1α,25(OH)2D3 action, we
treated MVs with detergent or 1α,25(OH)2D3, followed by treatment with RNAase. MVs isolated
in 0.9% NaCl were pooled together, the protein content, as determined by micro BCA assay,
normalized to 45 µg/mL, and samples then aliquoted out into micro centrifuge tubes (six samples
per group). The treatment was added to each tube (0.9% NaCl, Tween 20 + RNase,
1α,25(OH)2D3, or 1α,25(OH)2D3 + RNase) bringing the total sample volume to 100 µL and the
tubes were incubated in a 37˚C water bath for three hours. 700 μL of Qiazol lysis reagent was
added to each sample and processed with Qiagen’s miRNeasy micro kit. RNA was eluted in 30
μL of nuclease free water per sample.
RNA was quantified with a RNA 6000 pico chip on a BioAnalyzer. The generated pseudo
gel images were analyzed for specific band region using Licor’s Image Studio Lite software
(LICOR, Lincoln, NE).
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MV Endocytosis
MVs and 0.9% NaCl were stained with PKH26 (Sigma) as follows. MVs were normalized
to 75 μg/mL of protein and 120 μL of MV solution or 0.9% NaCl was added to 400 μL of diluent C
(Sigma) in each ultracentrifuge tube. 2 μL of PKH26 dye mixed with 500 μL of diluent C was
added to each ultracentrifuge tube and the mixture was allowed to sit at room temperature for 4
min (pipetting every 90 sec to mix). 1 mL of sterile filtered 1% BSA in PBS was added to quench
the remaining PKH26 and then 8 mL of DMEM FM (without ascorbic acid) was added. The
solution was ultracentrifuged (100,000g for 70min at 4˚C), the supernatant was discarded and the
remaining red pellet resuspended in 100 μL sterile DPBS.
GC cells were grown to third passage and then passed onto 8 well glass chamber slides
for the fourth passage. At 100% confluency the media were replaced and the stained MV and
NaCl solutions were combined with either 1α,25(OH)2D3 or vehicle and used to treat the cells for
24 hours. All media were removed, wells were washed twice with 1X PBS, fixed with 300 μL 10%
neutral buffered formalin for 30 min at room temperature, and counterstained with 100 μL 5 μM
DRAQ-5 in 1X PBS for 27 min at 37˚C. The chamber and gasket were removed from each slide,
Fluoro Gel with DABCO (EMS, Hatfield, PA) mounting media were added and then a coverslip
attached. One image per well was taken on a LSM 880 confocal microscope (Zeiss, Jena,
Germany) using a 20x objective for quantification and a 63x objective coupled with an airyscan
detector for high resolution imaging.
Quantification was performed by two independent and blinded observers. The images
were overlaid with a 3x3 grid and each observer counted the number of DRAQ5 stained nuclei
and the number of cells with six or greater distinct PKH26 spots. The percent stained cells was
calculated for each image and the average of both observers used for quantification. Additionally,
CellProfiler 3.0 was used for automated quantification of the images.[173]
Statistical Analysis
MV microRNA release and alkaline phosphatase activity are presented as mean ±
standard error of the mean for six samples for each group. An ANOVA with Tukey HSD post-hoc
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test was used to examine differences between the groups. Significance was determined by a p ≤
0.05.
Results
1α,25(OH)2D3 Regulates Chondrocyte Cellular and MV microRNA
Enrichment of alkaline phosphatase specific activity in MVs compared to that of the
plasma membrane was used to validate the MV preparation. MVs are isolated right-side out from
the ECM whereas plasma membranes that are isolated both right-side and wrong-side out from
cell lysates. Thus, specific activity of alkaline phosphatase, which is an exoenzyme, in MVs should
be a minimum of twice that of the enzyme activity in plasma membranes (Supplemental Fig. 3.1).
A comparison of the 14 samples (3 cells+vehicle, 3 cells+1α,25(OH)2D3, 3 MVs+vehicle,
3 MVs+1α,25(OH)2D3, and 2 FBS exosomes) with principle component analysis (PCA) and a
heatmap indicates that there are three distinct clusters, one for each sample type (cell, MV and
exosome depleted FBS) (Fig. 3.1). There is visible difference between the main sample types
(cell, MV & exosome depleted FBS) in the heatmap with the cell samples clustering in the first six
columns, the MV samples in the following six and the exosome depleted FBS samples in the final
two (Fig. 3.1 A). The microRNA can be divided into four distinct clusters as indicated on the yaxis. The sample grouping is also clearly visible in a principle component analysis with the sample
types clustering on the x and y axes that together accounts for 90% of the variance between
samples (Fig. 3.1 B). The exosome depleted FBS samples formed distinct clusters separate from
both cell and MV groups and were not included in the differential expression analysis.
Examination of the differentially expressed (p-value ≤ 0.05 and absolute log 2 fold change
≥ 1) microRNA between parent cells and MVs indicated a selectively exported population of
microRNA in the MVs with 211 differentially expressed in the vehicle group and 198 in the
1α,25(OH)2D3 group (Fig. 3.2 A,B,C). Of these microRNA, 44 were uniquely differentially
expressed in the vehicle group and 31 in the 1α,25(OH)2D3 group (Fig. 3.2 D,E). The 167 shared
MV microRNA were found to be selectively exported in identical fashion between vehicle and
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1α,25(OH)2D3 groups (same set of microRNA enriched in the MV as compared to cell samples
between vehicle and 1α,25(OH)2D3 groups) (Fig. 3.2 F).

Figure 3.1 (A) Heatmap of sample z-scores clustered with the complete linkage method and euclidean
distance measure. (B) PCA plot of components 1 & 2 for all 14 samples.
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Figure 3.2 Differentially expressed microRNA (p-value ≤ 0.05 & absolute log 2 fold change ≥ 1). (A)
Comparison between cell & MV with vehicle treatment, complete results. (B) Comparison between cell &
MV with 1α,25 treatment, complete results. (C) Venn diagram displaying overlap of differentially
expressed microRNA. (D) MicroRNA between cell & MV with vehicle treatment that are not differentially
expressed when treating with 1α,25. (E) MicroRNA between cell & MV with 1α,25 that are not differentially
expressed when treating with vehicle. (F) Differentially expressed microRNA that are shared in common
between vehicle and 1α,25 treatments.

The microRNA populations within the cell samples had only one differentially expressed
microRNA between the vehicle and 1α,25(OH)2D3 groups (Fig. 3.3 A). The MV samples however
had 18 differentially expressed microRNA between the vehicle and 1α,25(OH)2D3 groups (Fig.
3.3 B). Table of differentially expressed microRNA that were discovered between the four
comparisons (only the unique microRNA exported from the cell to MVs with and without treatment
and the entire set of differentially expressed microRNA between cells and MVs with and without
1α,25(OH)2D3) (Table 3.1).
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Figure 3.3 Differentially expressed microRNA (p-value ≤ 0.05 & absolute log 2 fold change ≥ 1). (A)
Differentially expressed microRNA when comparing cell populations with vehicle or 1α,25 treatments. (B)
Differentially expressed microRNA when comparing MV populations with vehicle or 1α,25 treatments.
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Table 3.1 Differentially expressed microRNA (p-value ≤ 0.05 & absolute log 2 fold change ≥ 1). Columns
1 & 2: Unique microRNA exported in MVs with vehicle or 1α,25 treatment. Columns 3 & 4: differentially
expressed when directly comparing cell or MVs.

miEAA analysis of the differentially expressed microRNA (between cell vehicle and cell
1α,25(OH)2D3, MV vehicle and MV 1α,25(OH)2D3, microRNA uniquely packaged following
1α,25(OH)2D3 treatment, and microRNA uniquely packaged following vehicle treatment) resulted
in large numbers of potentially impacted pathways, targeted mRNA, related diseases and tissue
locations for three of the four comparisons (no results were returned for the first comparison) (Fig.
3.4 A-C). Searching the initial results that covered the entire organism for musculoskeletal specific
terms (Supplemental Table 3.1 A) significantly reduced the pathways and mRNA involved (Fig.
3.4 D-F).

Figure 3.4 Visualization of miEAA search results of differentially expressed microRNA. (A, B & C)
Unfiltered results. (A) Between MV with vehicle or 1α,25 treatment. (B) Uniquely exported from cell to MV
with 1α,25 treatment. (C) Uniquely exported from cell to MV with vehicle treatment. (D, E & F) Results
filtered for musculoskeletal search terms. (D) Between MV with vehicle or 1α,25. (E) Exported from cell
to MV with 1α,25 treatment. (F) Exported from cell to MV with vehicle treatment.
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Loading the microRNA expression tables into ingenuity pathway analysis (IPA) indicated
that three chondrocyte pathways were being regulated by the microRNA populations: the
proliferation of epiphyseal chondrocytes, the maturation of chondrocytes, and development of
osteoarthritis (Fig. 3.5 A). Addition of vehicle to the cells promoted proliferation whereas addition
of vehicle + 1α,25(OH)2D3 to the cultures promoted cell and MV microRNA associated with
maturation and osteoarthritis (Fig. 3.5 B). A comparison of the cell miRNA with the miRNA in the
MVs they produce showed that cell miRNA drive proliferation whereas MV miRNA promote
maturation and osteoarthritis pathways.

Figure 3.5 Ingenuity pathway analysis results from differentially expressed microRNA. (A) Three
chondrocyte effected pathways listing the impacted microRNA families and a sample interaction network
for maturation of chondrocytes. (B) Table indicating which group is driving the pathway upregulation
between the four differential expression comparisons.
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1α,25(OH)2D3 Does Not Cause microRNA Release from MVs
Treatment of MVs with Tween 20 followed by RNase demonstrated that loss of membrane
integrity and protein denaturing exposed smallRNA to enzymatic degradation, as demonstrated
in RNA pseudo gels from a BioAnalyzer. Examination of the smallRNA region of the pseudo gel
showed that the RNA bands for the tween 20 + RNase group had clear degradation when
compared to negative control (0.9% NaCl), 1α,25(OH)2D3, and 1α,25(OH)2D3 + RNase groups
(Fig. 3.6 A). Quantifying the smallRNA region of the gels using Licor’s Image Studio Lite confirmed
that there was a significant reduction in RNA for the tween 20 + RNase group when compared to
all other groups (Fig. 3.6 B & Supplemental Fig. 3.2).

Figure 3.6 MicroRNA release from MVs with 1α,25 treatment. (A) Bioanalyzer gel results from MV
samples. (B) Quantification of small RNA signal region. Mean ± SE, groups not sharing a letter are
statistically different (α=0.05). NC: negative control, no treatment.

1α,25(OH)2D3 Promotes MV Endocytosis
The PKH26 dye was able to successfully stain GC cells in all treatment groups, visible at
20X (Fig. 3.7 A). Manual and automated quantification produced results with the same statistical
trends with MV + 1α,25(OH)2D3 staining more cells than NC + 1α,25(OH)2D3 (Fig. 3.7 B, C). When
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increasing the threshold for a stained cell up to 30 distinct spots on the automated quantification
data, MV with 1α,25(OH)2D3 was greater than both MV + vehicle and NC + 1α,25(OH)2D3 (Fig.
3.7 D). High resolution view of stained MV + 1α,25(OH)2D3 cell with a cloud of distinct green spots
(Fig. 3.7 E).
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Figure 3.7 MV Endocytosis. (A) Representative images from each of the four groups: PKH26 stained
MVs with 1α,25, PKH26 stained MVs with vehicle, PKH26 stained saline with 1α,25 & PKH26 stained
saline with vehicle. (B) Percent of cells stained with 6+ PKH26 spots from human counting. (C) Percent
of cells stained with 6+ PKH26 spots using cell profiler pathway. (D) Percent of cells stained with 30+
PKH26 spots using cell profiler pathway. (E) High magnification images of chondrocytes stained treated
with PKH26 stained MVs with 1α,25. Mean ± SE, groups not sharing a letter are statistically different
(α=0.05). NC: NaCl treated with PKH26. MV: MVs treated with PKH26.

Discussion
1α,25(OH)2D3 has been known to have a strong regulatory impact on the growth plate and
this study further expands on its regulatory capabilities with respect to GC cells and MVs.
MicroRNA packaged into MVs was demonstrated to be under the regulatory influence of
1α,25(OH)2D3. In contrast, 1α,25(OH)2D3 had little effect on microRNA within the cells. This was
demonstrated by the one differentially expressed microRNA when comparing the cell population
treated with vehicle or 1α,25(OH)2D3. 18 microRNA were found to be differentially expressed
between the two MV populations and around 200 when comparing the cells and the MVs they
produced. We used these groups of differentially expressed microRNA to explore what known
pathways are potentially being regulated. These were trimmed down to musculoskeletal related
pathways and we found that just over half the microRNA have previous connection to
musculoskeletal tissues (47 of 91) and of the 37 microRNA selectively exported in MVs known to
be found in musculoskeletal tissues only 16 have known mRNA or pathways. There was a limited
set of chondrocyte related pathways found to be connected to the exported microRNA using the
IPA software with proliferation, osteoarthritis and maturation being the only previously established
connections.
MicroRNA were found to be protected from RNAase activity within MVs with or without
1α,25(OH)2D3. Adding tween 20 detergent to the solution rendered the microRNA vulnerable to
degradation while adding 1α,25(OH)2D3 to the solution resulted in no discernable degradation.
MVs stained with PKH26 were visible bound to GC cells under confocal imaging and the
addition of 1α,25(OH)2D3 to cell culture during treatment increased the number of MVs binding to
and being endocytosed by GC cells. Distinct green dots, likely clusters of MVs, were visible in the
MV + PKH26 samples under high magnification and appeared to surround the cell’s nucleus.
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The role of 1α,25(OH)2D3 in modulating microRNA within the growth plate appears to be
primarily through the coordinated production of microRNA by GC cells followed by the selective
packaging of microRNA into MVs. 1α,25(OH)2D3 is potentially acting through both genomic and
nongenomic avenues within GC chondrocytes to achieve this regulatory effect. In altering the MV
microRNA population, 1α,25(OH)2D3 has the means to modulate a wide array of pathways well
downstream of MV packaging and export. Depending on growth plate stage, this regulation may
well be exerted on bone forming cells during vascular invasion and matrix turnover.
We examined the microRNA being exported into MVs in order to assess the likelihood of
them regulating cartilage or bone. It has been well established that each microRNA is able to
impact numerous pathways depending on their binding complementarity and what pathways are
currently active within the cell. The differentially expressed microRNA in the GC MVs are no
exception and this was validated by miEAA bioinformatic analysis, which returned numerous
cartilage and bone associated pathways that are likely impacted by these microRNA. Interestingly
the majority of selectively exported microRNA that are associated with musculoskeletal terms do
not have any pathways or mRNA linked to them (12 of 17 for 1α,25(OH)2D3 export and 9 of 20 for
vehicle export) and for exported microRNA only half have any known musculoskeletal
connections (17 of 30 for 1α,25(OH)2D3 export and 20 of 44 for vehicle export).
1α,25(OH)2D3 has a quantifiable impact on the microRNA population found in MVs. The
impact is most pronounced when looking at the microRNA that are being exported by the cells as
opposed to comparing within the cell and MV samples as indicated by the PCA plot. One cellular
microRNA was differentially expressed in response to 1α,25(OH)2D3. This stands in stark contrast
to the roughly 200 microRNA differentially expressed between MVs and their parent cells. When
examining the pathways that are potentially impacted by the set of differentially expressed
microRNA we found thousands of pathways that we were able to trim down to hundreds of
pathways using a manually curated set of musculoskeletal specific search terms. This resulted in
a set of microRNA with associated pathways and / or mRNA, another set of microRNA that were
just associated on a tissue level and had no pathways or mRNA associated with them, and a final
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set of microRNA that were differentially expressed in our study but have no known containing
musculoskeletal terms. All three groups of microRNA are clear avenues of further investigation in
order to understand what pathways they are in fact modulating in chondrocytes and potentially
bone forming cells.
MV microRNA have been demonstrated to be distinct populations when compared to the
cells that produced the MVs and are able to impact the phenotype of chondrocytes in vitro. How
these microRNA are making their way back to the chondrocytes to exert a regulatory influence
remains unclear. 1α,25(OH)2D3 has been demonstrated to release the content of MVs by
destabilizing the membrane and MVs are able to safeguard the microRNA cargo from RNase
digestion. In beginning to examine the route that microRNA may take from MV to cell we treated
harvested MVs with 1α,25(OH)2D3 in the presence of RNase to see if the microRNA is being
released into solution. Surprisingly the 1α,25(OH)2D3 + RNase treatment did not result in
increased RNA degradation indicating that the microRNA may be bound to protective carrier
proteins within the MVs, bound to the inner leaflet of the MVs, or the MV population may be
heterogeneous with some MVs reacting to 1α,25(OH)2D3 and releasing their contents into the
matrix and others remaining intact with their cargo that includes microRNA.
Examining MV endocytosis by chondrocytes following fluorescent staining we observed
an apparent increase in cells with distinct spots of PKH26 staining in the MV group as compared
to the negative control. This was not statistically significant in the quantification of the images as
there was a high degree of variability in the results and some background PKH26 staining in all
groups. The background staining did not show up in any control images taken without PKH26
stain and so is not likely to be autofluorescence. Both the NC and MV groups had a visible red
pellet that was resuspended for the cell treatment likely exposing all cells to a mix of bound and
unbound PKH26. With the automated quantification results we were able to adjust the threshold
for what is counted as a stained cell from 6 to 30 spots and this resulted in greater reductions for
the NC vehicle, NC 1α,25(OH)2D3 and MV vehicle groups compared to MV 1α,25(OH)2D3.
Treatment with 1α,25(OH)2D3 may be making the cells and/or the MVs more available for
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endocytosis and as a result increasing the percent of cells with high concentrations of stained
vesicles. Alternatively, the MVs may be rupturing as a result of 1α,25(OH)2D3 treatment increasing
the number of distinct spots observed on the cells. A high resolution view of the cells demonstrates
the distinct spots of PKH26 staining visible in the area around the counterstained nuclei.
Our results were not able to resolve the question of how the microRNA are gaining access
to the chondrocytes to perform their regulatory role though we were able to demonstrate that the
microRNA packaged within MVs is provided with protection from RNase. With the microRNA
remaining protected from degradation we have additional emphasis to the intentional packaging
of microRNA in MVs and additional questions as to the route taken by the microRNA on their way
into the chondrocytes. With the high resolution images that involved stained MVs we were able
to see what appears to be vesicles or vesicle fragments (the microRNA may be bound to the
interior of the lipid bilayer) adhering to the cell membrane. The stained MVs are found a distance
away from the stained nucleus and appear to be bound to or passing through the cell membrane.
1α,25(OH)2D3’s role continues to become more complex and integral to the overall
functioning of the growth plate. As the cellular population of microRNAs are experiencing virtually
no observable impact as a result of 1α,25(OH)2D3 treatment this regulation is likely happening
through a coordinated combination of genomic and non-genomic pathways that regulate both the
production and packaging of microRNA into MVs. How these exported microRNA are able to
regulate not only growth plate chondrocytes but osteoblasts and other cells integral to bone
growth could have numerous clinical applications. Gaining a more complete understanding of the
role, if any, that 1α,25(OH)2D3 plays in MV microRNA release would be useful in any therapeutic
application involving vesicles. Specifically understanding if the microRNA are contained / bound
to a carrier protein, attached to the interior leaflet of the MV membrane or simply within a
population of vesicles that don’t respond to 1α,25(OH)2D3 will be essential to developing any
microRNA based treatments. However, the increase of MV staining on chondrocytes following
1α,25(OH)2D3 treatment does indicate that 1α,25(OH)2D3 may be a key component of any vesicle
based microRNA treatments to aid in endocytosis and increase delivery to the cells.
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Supplementary materials

Supplementary Table 3.1 Search terms used on miEAA results.

Supplementary Figure 3.1 Alkaline phosphatase activity in cell pellet (CP), plasma membrane (PM)
and matrix vesicle (MV) samples with either vehicle or 1α,25 treatment. Mean ± SE, groups not sharing
a letter are statistically different (α=0.05).
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Supplementary Figure 3.2 Bioanalyzer gel quantified with Licor’s Image Studio Lite software.
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Specific microRNA–mRNA Complex Pulldown from
Growth Zone Chondrocytes

In process

Abstract
MicroRNA are able to regulate mRNA through the RISC and typically bind to the target
mRNA’s 3` UTR. The binding is occurring through the microRNA’s ~8 base long seed region
which prohibits translation of the sequestered mRNA and with sufficient complementarity the
mRNA ends up degraded by the RISC. Determining the phenotypic effects of a microRNA on a
cell population depend on the cell’s active transcriptome and the competing microRNA that are
active in the cell. Going from microRNA prediction databases to accurate phenotypic responses
remains a challenge. This study selected microRNA that have been found to be exported within
MVs in the growth plate and construct a protocol to accurately determine the mRNA under their
regulation. Biotin tagged microRNA LNA triple stranded mimics were transfected into GC cells
and then pulled down with streptavidin coated magnetic beads 48 hours later. The RNA was
isolated and sequenced on a desktop sequencer producing long read data that was aligned to
the transcriptome. The resulting genes were analyzed for differential expression against the
negative control group and the microRNA to mRNA 3` UTR binding energies estimated. The
differentially expressed up-regulated mRNA was used for pathway analysis. Genes were found
to be significantly differentially expressed between the five microRNA groups and the negative
control with minimal overlap between them. The microRNA to mRNA minimum binding energies
were found to be within range of what is considered possible mRNA targeting. This study provides
a fairly direct method of assessing some of the mRNA that are being regulated by a specific
microRNA within a certain cell type. Doing this in vitro allows the active transcriptome to accurately
regulate what mRNA are available for regulation and provides a good starting point for
investigating the potential phenotypic effects of a specific microRNA.
Introduction
The majority of mammalian skeletal growth occurs through the process of endochondral
ossification where mesenchymal stromal cells condense and form a cartilage template populated
by chondrocytes that mature, differentiate, and trigger mineralization of the ECM that is
subsequently turned over into bone.[12,161] This process contains distinct phases where cells

Asmussen | MicroRNA in the Mammalian Growth Plate: Matrix Vesicles and 1α,25-Dihydroxyvitamin D3

99

and the matrix undergo measurable changes. Chondrocytes form into columns as they transition
through the growth plate from proliferating cells in the RC to hypertrophic cells within the GC.[91]
The composition of the matrix changes from one rich in collagen type II and sGAGs in the RC to
one dominated by collagen type X and ALP in the GC.[24,131,174] Throughout this process
chondrocytes are producing matrix vesicles (MV) and releasing them into the growth
plate.[19,43,57]
MVs were initially discovered as focal points of tissue mineralization with hydroxyapatite
crystals growing through the lipid membrane.[90] Subsequent research has discovered that MVs
have a unique composition and cargo dependent on the parent cell’s stage of maturation. MVs
appear to bud of laterally from chondrocytes though the composition of their lipid membrane is
distinct from that of the parent cell.[175] The cargo carried by MVs includes minerals and enzymes
vital to the mineralization process but also contains factors for chondrocyte regulation, enzymes
that facilitate in ECM turnover and factor activation, and microRNA for chondrocyte
regulation.[9,36,37]
MicroRNA are short strands of RNA that are involved in the regulation of protein production
within cells. Once in the cytoplasm they are loaded into the RISC as ~22 base long single strands
of RNA.[66] Depending on the binding complementarity of a ~8 base long seed region within the
microRNA to cytoplasmic mRNA the mRNA is either sequestered or degraded by the
RISC.[67,68] MicroRNA are typically not limited to one specific mRNA and as a result can have
a wide array of effects depending on the cell’s current transcriptome.[68] This enables microRNA
to have varying regulatory effects based on cell type and stage of maturation while also making
a purely bioinformatic approach to target prediction and phenotypic effect increasingly difficult.
Additionally, microRNAs are able to target multiple distinct pathways within one cell.
MV microRNA has been demonstrated to be a population distinct from the parent cell and
to not only vary based on chondrocyte maturation level but fall under the regulatory control of
1alpha,25 dihydroxyvitamin D3 [1α,25,(OH)2D3].[2,55](Asmussen et al. Under Review) These
microRNA are capable of regulating the phenotype of both RC and GC chondrocytes indicating
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that target pathways for the microRNA are active within the chondrocytes. It remains unclear how
these microRNA find their way into chondrocytes (or possibly cells of the bone forming complex)
though their selective export from chondrocytes into MVs with some microRNA being found
almost exclusively in the cell or MV populations, their protection from RNase in MVs even
following 1α,25,(OH)2D3 treatment, and the increase in MVs adhering to chondrocytes when
treated alongside 1α,25,(OH)2D3 all point to intentional export of the microRNAs for the purpose
of downstream regulation. (Asmussen et al. Under Review)
Some of the selectively exported microRNA have known or predicted target mRNAs and
pathways within chondrocytes and other cells of the musculoskeletal tissues. However
comprehensive targets for the microRNA remain incomplete and a large portion of the microRNA
have no known or predicted targets within musculoskeletal tissues.
With the high likelihood of these microRNA performing regulatory functions on the growth
plate chondrocytes and the potential for engaging these as treatments for growth plate disorders
and possibly for use with articular cartilage it is important to gain a more complete understanding
as to their direct regulatory role. What chondrocyte mRNA are being impacted by select
microRNA? This study aims to provide a in vitro approach to answering this question using
microRNA mimic transfection, RISC pulldown, and a tabletop long read sequencer.
Methods
Chondrocyte Cultures
Chondrocyte cells were isolated from male 100 to 125 g Sprague Dawley rats as has been
previously detailed by Boyan et.al.[8,91] Animal procedures connected with this work were
approved by the Institutional Animal Care and Use Committee at Virginia Commonwealth
University. In brief, rats were killed by CO2 asphyxiation followed with cervical dislocation. Sharp
dissection was used to remove the rib cages and trim excess tissue. Ribs were placed in
Dulbecco’s modified Eagle’s medium (DMEM, Life Technologies, Carlsbad, CA) 1 g/L glucose,
150 U/mL penicillin and 150 μg/mL streptomycin and kept on ice. Under a dissection microscope
all tissue was cut from around the ribs and the cartilage adjacent to the bone cut into slices
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separating out GC and RC sections discarding one or two transition slices. Slices were incubated
(37 ˚C and 5% CO2) overnight in 1 g/L glucose DMEM with 10% FBS, 50 U/mL penicillin, 50
µg/mL streptomycin. The following day the slices were washed twice with Hank’s Balanced Salt
Solution containing 50 U/mL penicillin and 50 μg/mL streptomycin then incubated in 0.25 %
trypsin-EDTA (Gibco, Gaithersburg, MD) for 1 hour, washed once as before and incubated (37
˚C and 5% CO2) in 0.2% collagenase type II (Worthington Biochemical, Lakewood, NJ) on a
shaker for 3 hours. Cell solution was passed through a 40 μm nylon mesh strainer, FBS added to
10% and cells pelleted by centrifugation (500 x g, for 10 minutes) followed by resuspension with
DMEM FM (1 g/L glucose DMEM with 10% FBS, 50 U/mL penicillin, 50 µg/mL streptomycin, and
50 µg/mL ascorbic acid). Cells were counted and then plated with a density of 20,000 cells/cm2
for GC and 10,000 cells/cm2 for RC. Cells were incubated (37 ˚C and 5% CO2) and media
changed 24 hours after plating and then every 48 hours. Fourth passage cells were used for all
experiments.
LNA Transfection
Fourth passage GC chondrocytes were grown to 70% confluency, media were aspirated
and replaced with DMEM 1X with 10% FBS. Triple stranded LNA mimics biotinylated at the 3`
end (Qiagen, Hilden, Germany) were diluted 100 fold to 666.7 nM in DMEM and combined 1:1
with a solution of lipofectamine RNAiMAX transfection reagent (Invitrogen, Carlsbad, CA) that
had been diluted 26 fold in DMEM. This solution of mimics and lipofectamine sat at room
temperature for 20 minutes. Cells were treated with transfection solution for a further 1:10 dilution
bringing final LNA concentration to 32.6 nM. For concentration trial the LNA mimic solution was
diluted 1.5X four times before combining with lipofectamine solution for final concentrations of
32.6, 21.8, 14.5, 9.7, and 6.5 nM. For DNA isolation cells were incubated in transfection media
for 24 hours before changing media to DMEM FM for another 48 hours of incubation. For RISC
pulldown the cells were incubated in transfection media for 48 hours before the cells were lysed
and the LNA pulled down.
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DNA Quantification
Media were aspirated and cell layer washed twice with 1X PBS. 100 µL of 0.05% triton-x
100 in H2O was added per well and the plate moved to -80 ˚C for storage. Samples were thawed
on ice and sonicated (40 amps, 10 sec per well). QuantiFluor dsDNA system (Promega, Madison,
WI) was used for quantification following standard protocol with samples run diluted 1:10 and read
on a plate reader (Synergy H1 Hybrid Reader, BioTek, Winooski, VT) with excitation of 485 nm
and emission of 538 nm.
RISC PullDown and RNA Isolation
Protocol based on Dash et. al., in brief.[176] 30 µL per sample of streptavidin coated
magnetic beads (Pierce, Waltham, MA) were washed the day before cell harvest (3 washes with
100 µL of 10 mM Tris-Cl pH 7.5, 0.5 mM EDTA, 1 M NaCl solution and 3 washes with 100 µL
solution of 0.1 M NaOH, 0.05 M NaCl), resuspended (100 µL solution of 0.5 M NaCl), and blocked
(200 µL of 1 μg/μL BSA, 2 μg/μL Yeast tRNA solution) overnight in 4 ˚C. Cells were removed from
flasks with trypsin, pelleted (1,500 x g for 5 min at 4 ˚C), washed with sterile 1X DPBS, pelleted
again as before, and resuspended in 600 µL lysis buffer (150 mM NaCl, 25 mM Tris-Cl pH 7.5, 5
mM DTT, 0.5% IGEPAL, 60 U/mL Superase, 1x Protease Inhibitor Cocktail) before being rapidly
frozen in -80 ˚C and then thawed on ice. Cellular debris was pelleted (16,000 x g for 5 min at 4
˚C) and supernatant combined with ¼ volume of 5 M NaCl to generate cell lysate solution. Beads
from previous day were washed three times with 150 µL of pulldown wash buffer (10 mM KCl, 1.5
mM MgCl2, 10 mM Tris-Cl pH 7.5, 5 mM DTT, 1M NaCl, 0.5% IGEPAL, 60 U/mL Superase, 1x
Protease Inhibitor Cocktail) and then resuspended in 300 µL of pulldown wash buffer. 300 µL of
cell lysate solution was incubated with 300 µL streptavidin coated beads for one hour at room
temperature. Beads were washed three times with 300 µL pulldown wash buffer and finally
resuspended in 100 µL of nuclease free water on ice. 700 µL qiazol (Qiagen) was added to each
tube before transferring to -80 ˚C. RNA was precipitated following miRNeasy micro kit (Qiagen)
protocol for animal cell samples. RNA was eluted in 30 μL of nuclease free water per sample.
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Library Preparation and RNAseq
RNA isolations were quantified with a RNA 6000 pico chip on a BioAnalyzer (Agilent,
Santa Clara, CA) and library prepared according to specifications of the PCR-cDNA Barcoding kit
(SQK-PCB109, Oxford Nanopore, Oxford, UK) for 12 samples and run on a Spot On Flow Cell
Mk 1 R9 (Oxford Nanopore) for 72 hours. High precision basecalling was carried out on
Nanopore’s MinIT running MinKNOW (21.05.24) and guppy (5.0.16).
Bioinformatic Analysis
Fastq files that were considered to have passed basecalling were transferred to VCU’s
high performance research computing core facility where reads were aligned using minimap2
(2.21-r1071) to Ensemble’s Rattus norvegicus transcriptome (Rnor_6.0) and quantified with
salmon (v1.5.2).[177,178] The count data was then analyzed in R (4.1.0), differential expression
determined using DESeq2 (1.32.0), PCA plots built with pca3d (0.10.2) and PCAtools (2.4.0),
Venn diagrams made with VennDiagram (1.6.20), stacked bar figures with bigPint (1.8.0), and
volcano plots with ggplot2 (3.3.5).[151,154,172,179–182] UTRdb was used to download the 3`
UTRs of the differentially expressed genes.[85] Specific microRNA sequences were downloaded
from mirBase.org.[80] RNAhybrid tool was used to determine the microRNA to mRNA 3`UTR
minimum binding energies.[84] Pathway analysis was carried out using the PANTHER
classification system (16.0) webtool.[183]
Statistical Analysis
DNA quantity is presented as mean ± standard error of the mean for six samples for each
group. An ANOVA with Tukey HSD post-hoc test was used to examine differences between the
groups. Significance was determined by a p ≤ 0.05.
Results
microRNA 22-3p & 122-5p Concentration Trials
In determining optimal transfection concentration we transfected with different amounts
(6.5, 9.7, 14.5, 21.8, and 32.6 nM) of scrambled negative control (NC), 22-3p, and 122-5p LNA
mimics along with a no treatment control (NT) and the corresponding MirVana mimic (Thermo
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Fisher, Waltham, MA) at 14.5 nM whose concentration had been determined in a previous
study.[9] At 32.6 nM of LNA 122-5p we see an increase in DNA production nearly identical to what
is observed for transfection with MirVana mimic 122-5p, 32.6 nM of LNA NC is nearly identical to
NT group, and 32.6 nM of LNA 22-3p is slightly increased when compared to the MirVana mimic
22-3p (Fig. 4.1 A).
microRNA Mimic Selection
We selected five microRNA mimics that were highly exported into MVs from chondrocytes

Figure 4.1 LNA transfection and microRNA selection. (A) Transfecting NC, microRNA 22-3p, and
microRNA 122-5p LNA at concentrations of 6.5, 9.7, 14.5, 21.8, and 32.6 nM, and MirVana mimics of
each at 14.5 nM with two NT groups. (B) Table of fold change values from Cell to MV in two separate
experiments (one with 1α,25 treatment and one without). Mean ± SE, groups not sharing a letter are
statistically different (α=0.05). NC: negative control, NT: no treatment.

based on previous experiments[9,55] (Asmussen et al. Under Review) These microRNA exhibited
fold changes ranging from 2.19 to 2,352.53 when comparing the GC microRNA population with
the MVs that they produced (Fig. 4.1 B).
Sample Clustering
13,664 genes were returned from the alignment of the sequencing reads between all 24
samples. A PCA plot of these reads resulted in minimal clustering with just over 20% of variation
represented between PC 1 & 2 (Fig. 4.2 A). Examining the 502 differentially expressed genes
between each targeted microRNA and NC resulted in three distinct clusters with NC alone in one
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cluster, microRNAs 22-3p and 122-5p having minimal overlap in a second cluster and microRNAs
1-3p, 30c-5p, and 133a-3p grouping together in a third cluster (Fig. 4.2 B). A scree plot of the
differentially expressed genes shows that roughly 35% of variation is explained by PCs 1-3 (Fig.
4.2 C). This can be visualized in a 3d PCA plot which shows distinct clusters forming when viewed
with PCs 1-3 (Fig. 4.2 D).

A
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D

Figure 4.2 Sample clustering (A) PCA plot of all 24 samples with full set of 13,664 genes. (B) PCA plot
of all 24 samples with 502 differentially expressed genes. (C) Scree plot for the 502 differentially
expressed genes. (D) 3D PCA plot of PCs 1, 2, and 3 from two different viewpoints.

Differential Expression
MicroRNA groups (1-3p, 22-3p, 30c-5p, 122-5p, and 133-3p) are compared against NC
using DESeq2 with a cut off for differential expression of absolute log 2 fold change ≥ 1 and a pvalue ≤ 0.05. Results of all five comparisons are visualized in volcano plots with a horizontal line
at –log10(0.05) and vertical lines at log2(0.5) and log2(2) (Fig. 4.3 A-E). All five comparisons have
differentially up and down-regulated genes compared to NC. The differentially expressed up-
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regulated genes when viewed across the eight samples in the two groups in question have
minimal fluctuation within each group (Supplemental Fig. 4.1).

A

B

D

E

C

Figure 4.3 Volcano plots of differentially expressed genes between each of the five microRNA groups
and NC. (A) NC and microRNA 1-3p. (B) NC and microRNA 22-3p. (C) NC and microRNA 30c-5p. (D)
NC and microRNA 122-5p. (E) NC and microRNA 133a-3p. Horizontal red line at log10(0.05), vertical
red lines at log2(0.5) and log2(2) with the differentially expressed genes indicated by red for downregulated and blue for up-regulated.
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Examining the 502 differentially expressed genes between all five comparisons for overlap
415 of the genes are only differentially expressed within one comparison and 62 are shared by
two comparisons (82.7%) (Fig. 4.4 A). Of the 502 differentially expressed genes 165 of them are
increased in the microRNA sample compared to NC with 112 (67.9%) of these uniquely increased
within one microRNA and 33 (20.0%) shared between two (Fig. 4.4 B and Table 4.1). An
increased proportion of genes are uniquely decreased in one sample (307 out of 339 or 90.6%)
with 27 genes (8.0%) decreased in two microRNA groups (Fig. 4.4 C).
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B

C

Figure 4.4 Venn diagram of the differentially
expressed genes from all five comparisons to
NC. (A) All differentially expressed genes.
(B) Genes up-regulated in the microRNA
group compared to NC. (C) Genes downregulated in the microRNA group compared
to NC.
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Table 4.1 All of the differentially expressed up-regulated genes in the five comparisons to NC.

GO Pathway Analysis
All of the differentially expressed up-regulated mRNA were submitted to the PANTHER
online gene ontology tool to begin to examine the pathways they are connected to. The results
were searched for musculoskeletal related terms in order to filter down the 5,725 total pathways
that were returned. This left 25 pathways for microRNA 1-3p, 15 for microRNA 22-3p, 39 for
microRNA 30c-5p, 19 for microRNA 122-5p, and 21 for microRNA 133a-3p (Table 4.2).
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Table 4.2 Musculoskeletal related pathways connected to differentially expressed up-regulated mRNA
in the ‘label’ column and the number of genes associated with the particular pathway found in the
microRNA differential expression list in the ‘# of genes’ column.

microRNA to mRNA Binding Energy
The RNAhybrid command line tool was used to predict the MFE of the specific microRNA
with the differentially expressed upregulated mRNA’s 3` UTR when comparing the microRNA in
question with NC. The average MFE for all of the microRNA to target mRNA combinations is 20.8 kcal / mol (Fig. 4.5 A). The MFE prediction is based on the most advantageous binding
location estimated within the provided 3` UTR target sequence. A sample of the results is provided
with a corresponding range of MFE and p-value estimations (Fig. 4.5 B).
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Figure 4.5 MicroRNA to mRNA 3` UTR binding energies. (A) Histogram of the binding energies of all
up-regulated genes matched to their corresponding microRNA. (B) Representative samples of the range
of binding energies found between microRNA and mRNA 3` UTR.

Discussion
This study aims to establish an approach to gain a more complete understanding of what
impact specific microRNA may be having within certain tissues. The specific microRNA in
question are well studied and have long lists of predicted targets within the rat genome. We began
by analyzing the response of the GC cells to the biotin tagged LNA mimics of two previously well
studied microRNA. The higher concentration of LNA mimic was selected as it produced the most
consistent phenotypic response with our previous research and since the objective is to pulldown
active RISC the potential side effects of disproportionally occupying the RISC with the mimic was
not a large concern in this study.
Initial examination of the sequencing results produced 13,664 genes between the six
groups. Many of these genes had very low copy counts in the raw data and when selecting for
the 502 genes found to be differentially expressed between NC and the select microRNA we were
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able to get more distinct clustering of the six groups. The magnetic beads are blocked with yeast
tRNA to reduce off target RNA binding and during the pulldown procedure the beads go through
numerous wash steps as part of the RNA isolation procedure however this may only produce
incomplete reduction of noise in the actual pulldown.
The differentially expressed genes had both up and down-regulated sub populations in
comparison to NC and when all five comparisons were examined for overlap the majority of genes
were found to be unique within their respective group. The differentially expressed mRNA in this
study contain some predicted mRNA for the microRNA in question but are primarily genes not
found in the microRNA-mRNA prediction databases. To try and further evaluate the likelihood of
these being accurate mRNA targets we examined the MFE between each microRNA and the 3`
UTR of their differentially expressed up-regulated mRNA targets. The average MFE for all of our
microRNA to mRNA bindings was -20.8 kcal / mol which is slightly higher than the -25 to -30 kcal
/ mol that prediction algorithms often use.[86,87] Additionally a reference example of high-quality
binding provided with the RNAhybrid tool is between let-7 microRNA and hbl-1 mRNA producing
a MFE of -28.2 kcal / mol and a p-value of 0.064. While the average MFE of our microRNA is
slightly higher than what is commonly used for computational predictions it is certainly not outside
the bounds of possible microRNA to mRNA binding.
An initial pathway exploration found 5,725 different pathways associated with the
differentially expressed up-regulated mRNAs. Of these, 119 pathways are directly associated with
musculoskeletal tissues (e.g., “osteoblast differentiation” and “positive regulation of cartilage
development”) and chondrocyte behaviors (e.g., “vesicle cargo loading”). The total list of 5,725
pathways is tissue independent and requires filtering to obtain relevant information. Most of the
existing pathway analysis tools are designed around analyzing transcriptomic data that generally
has a complete, or nearly so, representation of the active transcriptome under study. Since we
are working with microRNA based pull down genes, we have a very incomplete representation of
the transcriptome and are instead examining a regulatory mechanism. This invalidates most of
the pathway tools designed to estimate likelihood of activity based on the genes in the sequencing
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results. We are essentially looking at the inverse – what could the effect of down-regulating these
specific genes have on the pathways that may otherwise be active within the cell.
The differentially expressed and up-regulated mRNA in this study provide a likely target
list for each of the specific microRNA used in the pulldown experiment. Additional pathway
analysis and interpretation is warranted to further understand what role the microRNA may be
playing within the chondrocytes followed by wet lab confirmation. This is also necessary to better
understand how transfecting specific microRNA will interact with the endogenous population of
microRNA within the cells. This work provides a solid basis of likely mRNA targeting by specific
microRNA that have been found to be selectively exported into MVs. The results, if confirmed,
also call further into question relying entirely on bioinformatic prediction tools for microRNA
targeting. We can see in the results from RNAhybrid that while the binding energies may not be
optimal for the microRNA to mRNA there are viable binding sites for all of the microRNA within
the 3` UTR of the differentially expressed mRNAs. Given that the mimics used were LNA based
which have a near irreversible binding chemistry it is possible that some off target binding took
place in the cytoplasm however the LNA is delivered in a ‘triple’ stranded configuration (where
the mimic’s passenger strand is composed of two separate and very short RNA strands that are
designed to produce minimal interference when the mimic is processed and loaded into the RISC)
and should remain triple stranded and unavailable to random mRNA binding until being processed
and loaded by the RISC. This study provides a valuable resource for better understanding the
direct role that microRNA will have in certain cells by making the targeted mRNA within this cell
population known allowing researchers to better predict and understand what pathways are likely
to be affected by a given microRNA.
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Supplementary materials
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Supplemental Figure 4.1 Stacked bar plots of the differentially expressed up-regulated genes. (A) NC
and microRNA 1-3p. (B) NC and microRNA 22-3p. (C) NC and microRNA 30c-5p. (D) NC and microRNA
122-5p. (E) NC and microRNA 133a-3p. Differentially expressed up-regulated genes have a p-value ≤
0.05 and log 2 fold change ≥ 1.
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Discussion
Studies contained in this thesis examine the role of MV microRNA in the growth plate from
different angles and support the likelihood of microRNA exported in MVs to be selectively
packaged, exported, and protected for the purpose of downstream cell regulation. Not all aspects
of the MV microRNA lifecycle were examined in this work, though the facets that we did examine
reinforced the selective export of microRNA as a regulatory factor within the growth plate while
also opening numerous potential avenues of further investigation. Additionally, we adapted
approaches that enabled us to investigate the in vitro interaction between individual microRNA
and the population of mRNA it targets.
Expanding on previous work in this lab we demonstrated zonal regulation of microRNA
expression and packaging. MicroRNA populations differ between the chondrocytes and MVs
found in the RC and GC zones. With microRNA being selectively exported by both RC and GC
chondrocytes the questions of what might be regulating the zonal production and packaging and
how these microRNA might be affecting chondrocytes in the growth plate arose. We hypothesized
that the microRNA with some of the highest fold change values for export into the ECM and lowest
p-values would be a good place to start looking for phenotypic changes. Additionally, the question
of what regulatory molecule might be regulating MV export was raised. Given what is already
known about 1α,25(OH)2D3 and MVs, it was decided to be a good starting point.
We began by transfecting chondrocytes (both RC and GC) with individual microRNA to
assess the potential for phenotypic changes. Starting with broad assays measuring total DNA
content, metabolism, and alkaline phosphate activity we noticed effects following transfection with
specific microRNA. The observed phenotypic effects were not something that could be correlated
to bioinformatic prediction lists with any degree of confidence as we didn’t observe a direct
connection between something like TNAP mRNA and microRNA 122-5p. We continued to assay
a wide range of proteins, factors, and responses following microRNA transfection and found
numerous surprising results including the regulation of Ihh, PTHrP, VEGF and TGF- β1 following
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transfection with microRNA 22-3p. microRNA 22-3p was also able to decrease total DNA
production and sGAG production in RC chondrocytes.
MicroRNA 122-5p had robust phenotypic effects on the chondrocytes with what became
a defining characteristic: the ability to increase various measures of chondrocyte proliferative
activity (as measured by total DNA production, EdU incorporation and MTT metabolism) were all
significantly increased following microRNA 122-5p transfection. Additionally, microRNA 122-5p
was able to decrease collagen II production and alkaline phosphatase activity in GC chondrocytes
as well as increase sGAG content to quantities similar to what is found in RC based chondrocytes
grown under the same conditions. Cumulatively, microRNA 122-5p appeared to be producing a
RC like phenotype in GC chondrocytes. The microRNA being examined were exported with
greater fold changes in GC as opposed to RC chondrocytes; however, with the exception of
microRNA 22-3p, they all appeared to be primarily exported into MVs and not kept within the cell.
How exactly exported microRNA find their way back into cells remains an open question,
in addition to what type of cell is it exported for? Could a portion or all of the GC MVs be exported
specifically for the zone of vascular invasion where bone forming cells are transported in by the
expanding vasculature and turn over the ECM where MVs may be residing? What responses
these different cell types might have to the exported microRNA may be worthy of future research
especially if any MV uptake by the bone forming cells can be documented.
The confirmation of phenotypic effects in growth plate cells in addition to the selective
export of microRNA made the question about a regulatory molecule for the production and
packaging of microRNA by chondrocytes more intriguing. We decided to start by examining the
response to 1α,25(OH)2D3 treatment of GC chondrocytes since 1α,25(OH)2D3 already has well
established roles with regards to GC MV production. The selective export of microRNA that was
observed in the initial study was repeated in this round of RNAseq and the suspected involvement
of 1α,25(OH)2D3 confirmed. While the bulk of exported microRNA was unchanged, a subset of
microRNA was robustly regulated by the hormone. Additionally, almost no impact was observed
on the cell population indicating that the production and packaging of the microRNA was being
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carried out in coordinated fashion leaving the chondrocyte microRNA population virtually
unaffected. This indicates that few if any immediate phenotypic effects from 1α,25(OH)2D3
treatment are likely attributable to an altered microRNA population. Examining RC cells for similar
response to 24R,25(OH)2D3 treatment would be an interesting follow up.
1α,25(OH)2D3 treatment of isolated MVs produced a somewhat surprising though
confirming result when the small RNA population remained protected from RNase activity. It was
expected that 1α,25(OH)2D3 treatment would cause MVs to become leaky and release their
contents making the once protected RNA molecules vulnerable to the RNase in solution.
However, the RNA remained protected and no degradation was observed. This provides
additional reinforcement to microRNA being a regulatory factor that is exported by chondrocytes
for downstream regulatory action. It would be interesting to discover how the microRNA remain
protected – if they are in a MV population that remains intact following 1α,25(OH)2D3 exposure or
if they have been released into the ECM in some form yet remain shielded from RNase. It could
also be useful in understanding the observed increase in stained MVs binding to chondrocytes
following 1α,25(OH)2D3 treatment. Does 1α,25(OH)2D3 trigger a response in the cells or MVs that
results in greater binding affinity of the MVs in solution and/or are the MVs beginning to break
apart and more fragments are able to bind cells as distinct points? Either option, or a combination
of the two, may well be aiding in the delivery of microRNA, as regulatory factors, to the GC
chondrocytes. Resolving some of these unknowns will be key for developing any potential clinical
application of vesicle bound microRNA.
Biotin tagged microRNA mimics were able to be transfected into cells, the microRNAmRNA complexes pulled down and the mRNA sequenced. The resulting gene lists, after being
filtered for differentially expressed up-regulated genes in the individual microRNA when compared
to NC, provided over five thousand potentially impacted pathways. These pathways are a great
starting point for additional wet lab testing to see if the microRNAs are able to impact the pathways
and produce a quantifiable phenotypic response. Following this it would be necessary to begin
examining the network effect that transfecting a group of heterogeneous microRNA has on
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chondrocytes as this is both how they are packaged within a MV population and would likely make
for the most impactful treatment option. However, the ability to determine what microRNA are
being exported by the cells and the genes and subsequent pathways that these microRNAs target
is all vital information to have when assessing microRNA for any therapeutic roles.
Demonstrating that exported microRNA have phenotypic effects on growth plate cells
(both RC and GC) and that their packaging into MVs by GC cells is being regulated by
1α,25(OH)2D3 provides further insight into the role of microRNA in the mammalian growth plate.
The regulation that 1α,25(OH)2D3 provides to MV release and subsequent endocytosis by GC
cells adds to the roles and complexity of 1α,25(OH)2D3 and MVs in the growth plate. Finally having
a more direct approach to determining the targets of individual microRNA within chondrocytes
aids in evaluating the potential effects of candidate microRNAs. All together the work presented
here provides a solid foundation to the role of MV microRNA within the growth plate, a regulatory
factor of MV microRNA, and an in vitro approach to evaluating the microRNA’s impact.
There are many further avenues of investigation that are opened by this work. There is no
existing bioinformatic approach to take investigators from differential microRNA expression to
phenotypic effect. Without more in-depth data on a given cell’s active transcriptome, beginning to
predict the impact of specific microRNAs will remain a challenge. As was demonstrated in this
work, this would only be the first step as the compounding downstream effects of microRNA
regulation would have to be accurately predicted as well. Targeted RISC pulldown allowed us to
partially bypass this issue and build a profile of regulated mRNAs. More extensive information is
available on mRNA expression results though even when following searches for related pathways
a significant amount of manual searching and curation of the results is required. This is a clear
next step for the differentially expressed mRNA from aim 3 of this work. Potentially impacted
pathways will require in-vitro confirmation before examining multiple select microRNAs for
complementarity effects. Of the five microRNAs examined in the RISC pulldown study the two
microRNAs (22-3p and 122-5p) from untreated cells in the first small RNAseq study were
clustered together while the three microRNAs (1-3p, 33c-5p, and 133a-3p) found to be
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differentially exported into MVs following 1α,25(OH)2D3 treatment were clustered together. This
treatment-based clustering of the differentially expressed mRNA could indicate an overall
synergistic effect from the microRNA. Are microRNAs that are exported together by GC cells
functioning in a cohesive manner? Additional RISC pulldown and transcriptomics studies of select
exported microRNAs would potentially add vital data to further address this.
As researchers continue to consider microRNA for clinical treatments more thorough
interrogation of their specific impact within cells and tissues is required. The ability to study the
mRNA that are being regulated by specific microRNA is a clear first step in this process.
Examining the impact of transfecting multiple microRNA simultaneously along with tissue specific
delivery vehicles for in vivo studies are logical next steps.
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Conclusions
This work confirms the hypothesis that the microRNA packaged in growth plate MVs have
a regulatory effect on both RC and GC chondrocytes resulting in effects that are both quantifiable
and relevant to the growth plate. Production of microRNA by GC chondrocytes and the packaging
of these microRNA into MVs is being regulated by 1α,25(OH)2D3. In addition to the core aspects
of the hypothesis we confirmed that MVs are able to protect RNA from degradation by RNase
when in solution and that the MV RNA remains protected following 1α,25(OH)2D3 treatment. This
provides added confidence that the microRNA exported in MVs are being released into the ECM
for downstream regulation of chondrocytes or potentially bone forming cells. Additionally
1α,25(OH)2D3 appears able to increase endocytosis of MVs by growth zone cells when incubated
together.
Given that there is a low number of known cartilage relevant pathways or mRNA
associated with the microRNAs of interest we were able to successfully adapt a RISC pulldown
approach to directly examine the binding between a specific microRNA and its mRNA targets.
This approach holds great promise for the continued screening of microRNA providing cell type
specific information on the mRNA that are being targeted.
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